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Abstract 
Introduction: Gonadotropin Releasing Hormone (GnRH) is a hypothalamic decapeptide, 
which regulates mammalian gonadotrophin secretions by binding to specific, high affinity 
receptors in the pituitary. Two forms of GnRH (GnRH I and GnRH II) are expressed in the 
brain of humans and some primates. GnRH I play a key role in the process of reproduction. 
After binding to its cognate receptor (GnRH I receptor), it stimulates the secretion of LH and 
FSH, which in turn regulate gonadal steroidogenesis and gametogenesis in both sexes. 
Clinically, some GnRH I analogues have been used as an effective treatment for a variety of 
reproductive disorders.  
 
The second form of GnRH (GnRH II) differs from GnRH I in that it is expressed at higher 
levels outside the brain. It seems to play an important role in reproductive functions since 
GnRH-like material has been observed in various reproductive cells and tissues such as 
human seminal plasma, follicular fluid, testis and prostate gland. In vivo primate studies have 
shown the contraceptive capabilities of GnRH II analogues and have identified different 
possible sites of action for fertilization disruption in the reproductive tract. In the male, one 
site could be the fertilizing sperm since a receptor was found in the acrosomal region. 
However, GnRH exposure to human sperm in vitro has been shown to enhance the ability of 
the sperm to bind to the zona pellucida of the oocyte.  
 
Even though primates have been used extensively in a variety of investigations in relation to 
the role of GnRH in reproduction, there is no evidence of any research to investigate the 
direct effect of GnRH on primate sperm. 
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Materials and methods: Semen from ten sexually mature Vervet monkeys was obtained by 
electro-stimulation applied per rectum. Motile sperm were selected through the swim-up 
technique in Hams F10 medium. Sperm samples were exposed to three different 
concentrations (10-5M, 10-6M and 10-8M) of GnRH I and GnRH II for one hour. Slides were 
stained with FITC/PNA for acrosomal integrity evaluation. The proportions of spermatozoa 
with fluorescent patterns were recorded for intact acrosome, equatorial staining and no 
acrosome. The results were expressed as percentages after evaluating 200 spermatozoa. 
 
Sperm motility was evaluated by computer-aided sperm motion analysis (CASMA), using 
the Sperm Motility Quantifier [version 1.01: Wirsam Scientific & Precision Equipment (Pty) 
Ltd, South Africa]. The parameters considered in this study were straight-line velocity 
(VSL), curvilinear velocity (VCL), linearity (LIN), average path velocity (VAP), mean 
angular displacement (MAD) and amplitude of lateral head displacement (ALH). 
 
Results: Neither GnRH I nor II affected acrosomal integrity in terms of any of the staining 
patterns for all concentrations and time intervals (immediate exposure to one hour). The 
percentage sperm motility was significantly decreased after one-hour exposure to both GnRH 
I and II at 10-8M.  
 
The changes in the CASMA variables revealed that immediate exposure (0-5 minutes), 
showed a statistically significant decline in VCL (p<0.05) and VSL (p<0.05) in groups 
treated with GnRH I & II 10-8M when compared to the control and Propylene Glycol 0,2% 
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(vehicle) groups. After fifteen minutes of GnRH I & II exposure at 10-8M, a statistically 
significant decline (p<0.05) was found in VCL, VSL, LIN, and ALH.  
 
After thirty minutes of GnRH exposure, VCL demonstrated a statistically significant 
decrease (p<0.05) in GnRH I & II 10-8M. VSL and VAP were also significantly decreased 
(p<0.05) but only for GnRH I at 10-8M.  
 
After sixty minutes of GnRH exposure, the statistically significant decline in groups treated 
with GnRH I & II 10-8M compared to the control was evident for all variables. However, 
MAD continued to increase, and was significantly different when GnRH II at 10-8M was 
compared to the control.  
 
Discussion: The results of this study showed that both GnRH I & II at the lowest 
concentration (10-8M) had an effect on the sperm motility in vitro. However, the high 
prevalence of intact acrosomes in all GnRH treated groups suggests that GnRH I & II have 
little or no effect on the functional changes in sperm plasma membrane composition.  
 
Conclusion: GnRH I and II inhibit motility of Vervet monkey sperm in vitro. It is postulated 
that sperm can be affected by GnRH in various parts of the female reproductive tract during 
transport to fertilize the egg. The results of this study suggest that GnRH could play a role in 
sperm motility modulation and selection.  
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CHAPTER 1 
Introduction 
 
1. General introduction and background to GnRH 
1.1 Classic role of GnRH   
GnRH is the central regulator of the reproductive hormonal cascade and was first isolated 
from mammalian hypothalamus. It is also known as Luteinizing Hormone Releasing 
Hormone (LHRH) or Mammalian GnRH I and controls the reproductive system through its 
stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion 
from the pituitary [Hazum and Conn 1988, Conn and Crowley 1994]. GnRH is one of the 
families of hormones and neurotransmitters, which require Ca²+ for their biological actions 
[Conn et al. 1986, Denef 1988]. The latter plays an important role in the pulsatile way GnRH 
is released into the systemic circulation. GnRH is synthesized in the hypothalamus and then 
transported in a pulsatile manner to the anterior pituitary through the hypothalamo-
hypophyseal portal system to bring about the release of the gonadotropins, LH and FSH, 
which, in turn, affect gonodal function [Huckle and Conn 1988, Clayton 1989]. This action 
of GnRH is achieved by binding to and activation of its high affinity receptors on the 
pituitary [Johnson and Everitt 1990, Clayton 1989, Stojilkovic et al. 1994]. The pulsatile-
timed and concentration levels of GnRH are critical for the maintenance of gonodal 
steroidogenesis and for normal reproductive function [Huckle and Conn 1988].  
 
The C-terminal portion of the GnRH molecule is necessary for attaching to the target 
receptor, and the first three amino acids are necessary for activating LH and FSH release 
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[Reeves 1987]. LH stimulates ovulation and corpus luteum formation in females [Moss and 
McCann 1973] and testosterone secretion in males. FSH stimulates the growth and 
maturation of ovarian follicles in females and spermatogenesis in males [Conn et al. 1986, 
Hazum and Conn 1988, Ganong 1999]. In addition to the orchestration of gonadal activity 
through the pulsatile release of LH and FSH from the anterior pituitary, GnRH may play an 
important role in the regulation of extra-pituitary physiological functions [Stojilkovic et al. 
1994]. The existence of GnRH and GnRH receptor mRNAs in normal human non-
reproductive tissues, suggests that GnRH may also be involved in the regulation of cellular 
function in an autocrine or paracrine manner [Emons et al. 1998, Kakar and Jennes 1995]. 
There is also strong evidence from several in vitro physiological studies that GnRH acts as a 
meiosis-stimulating factor in oocytes [Hillensjö and LeMaire 1980, Nabissi et al. 1997]. In 
mature granulosa cells, GnRH I is associated with stimulatory effects on oocyte cleavage, 
ovulation and luteinization [Von Schalburg et al. 1999, Nabissi et al. 1997] and evidence of  
enhancing sperm-zona binding, which is an essential step in the fertilization process [Morales 
1998]. 
 
A second form of GnRH (GnRH II) conserved in all higher vertebrates, including humans, is 
present in extra-hypothalamic brain and many reproductive tissues. GnRH II is thought to 
have an important regulatory role in gonadotropin secretion because it potently stimulates 
gonadotropin discharge in monkeys [Lescheid et al. 1997, Okada et al. 2003, Densmore and 
Urbanski 2003] and in the bullfrog [Wang et al. 2001]. The wide distribution of GnRH II in 
the brain, suggests important neuromodulatory functions [Millar et al. 2001] such as the 
contribution to regulating the primate reproductive system, which may also be under 
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neuroendocrine control from GnRH I [Lescheid et al. 1997]. GnRH II might be involved in 
the suppression of cell growth in tumour cell lines with an auto regulatory role on the rate of 
cell regulation and proliferation [Peng et al. 1994, Emons et al. 1989, Emons et al. 2000, 
Quyam et al. 1990, Azad et al. 1993], and yet may act as a growth or transforming factor that 
contributes to the promotion of prostate cancer in humans [Fekete et al. 1989]. Later studies 
also proved that GnRH II stimulates gonadotroph secretions, even though it is less effective 
than GnRH I [Okada et al. 2003, Densmore and Urbanski 2003]. 
 
In many vertebrate species, a third form of GnRH occurs which is localized to the forebrain 
in fish and is designated GnRH III. Its localization in the midbrain does support a central role 
in the regulation of gonadotropin secretion. The role of this third peptide in the 
hypothalamic-pituitary-gonodal axis may be conveyed by modulation of GnRH I activity, or 
by the regulation of GnRH I expression or release. It could also play a role as the 
physiological regulator of reproductive behaviour [Yahalom et al. 1999]. 
 
1.2 Novel locations and functions of GnRH 
1.2.1 Tissue distribution 
The pituitary is the gonatroph that expresses high affinity GnRH receptors and secretes 
gonatrophic hormones. GnRH functions not only as a releasing hormone and is distributed 
throughout the nervous system and other non-reproductive tissues [Rama and Rao 2001]. 
Due to the lack of a homogeneous in vitro model of gonadotropes, the cell line LβT2 was 
identified as a useful tool to investigate the cellular and molecular events during 
gonadotropin synthesis [Turgeon et al. 1996]. Using reverse transcriptase polymerase chain 
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reaction (RT-PCR) techniques, PCR products from GnRH were also obtained from human 
liver, heart, skeletal muscle, kidney, placenta and pituitary. The highest levels of GnRH II 
were reported in the kidney, prostate, and bone marrow. Compared to the brain, the levels in 
the kidney are approximately 30-fold higher and four-fold greater in bone marrow and the 
prostate [White et al. 1998]. 
 
Despite the apparent role of GnRH I in regulating reproduction, GnRH II is reported to be 
expressed in humans, and is 70% identical to GnRH I. It is expressed ubiquitously in human 
tissue with high levels outside the brain. GnRH I have not been observed at a high level 
outside the brain. GnRH II was also isolated in the brain of various mammals and in the 
mesencephalic cells of non-placental animals [Dong et al. 1996, Urbanski et al. 1999, 
Lescheid et al. 1997, Kasten et al. 1996 and Montaner et al. 1998]. Chicken GnRH (cGnRH) 
and GnRH I was shown to be expressed in the median eminence of the hypothalamus, a 
strategic location for its secretion into the circulation of the pituitary gland [Urbanski et al. 
1999]. GnRH neurons were present at the medial preoptic area (MPOA) and the medio basal 
hypothalamus (MBH) of the lemur (Microcebus murinus) [Aujard et al. 2005]. A third 
isoform of GnRH (GnRH III) is localized in the telencephalon of several fish and in the 
hypothalamus and midbrain of humans and calves [White et al. 1998].  
  
The GnRH gene is expressed in reproductive tissues such as the ovary, placenta, and 
mammary gland [Dong et al. 1993, Peng et al. 1994, Nabissi et al. 1997 and Von Schalburg 
et al. 1999]. The cDNA sequences of this peptide were shown to be identical in the placenta, 
the hypothalamus form [Seeburg and Adelman 1984], and the pituitary GnRH [Kakar et al. 
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1992]. Two types of GnRH-like factors are found in human seminal plasma [Sokol et al. 
1985] and in human testis, which differ in immunoreactivity from hypothalamic GnRH 
[DiMeglio et al. 1998]. It also acts on multiple extra-pituitary sites to regulate various 
reproductive functions and it has been identified in granulosa and theca cells of the rat ovary, 
and the Leydig cells of the rat testis. GnRH II was also localized in the testis, epididymis, and 
seminal vesicle and fallopian tube of the baboon [Siler-Khodr et al. 2003]. The peptide is 
also present in human granulosa-luteal cells [Peng et al. 1994] and a GnRH-like protein 
found in human ovaries showed similarities to the GnRH found in the rat ovary [Hsueh and 
Schaeffer 1985, Aten et al. 1987]. Compounds with GnRH-like activity were found in the 
ovary of the African catfish and sea bream [Habibi et al. 1994, Nabissi et al. 1997] and 
GnRH II was reported in the baboon ovary [Siler-Khodr et al. 2003]. 
 
Recent studies have shown that about 50% of breast and approximately 80% of ovarian and 
endometrial cancers express GnRH [Emons et al. 1998, Emons et al. 2000]. The presence of 
GnRH in rat and human experimental prostatic cancer, prostatic cancer cells in culture and 
biopsy specimens has also been reported. It was found that 68% of benign and 27% of 
malignant human prostate tissues contained a GnRH-like peptide [Quyam et al. 1990, Azad 
et al. 1993]. In 30% of biopsies from breast cancer patients, various hypothalamic hormones 
and GnRH were seen in the cytoplasm or in the nuclei of the tumour cells. The fact that these 
hormones were consistently found in premalignant and malignant lesions, but not in normal 
breast tissue, suggests the possibility that the hormones could be produced locally during the 
process of malignant transformation [Ciocca et al. 1990].  
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The findings that the tissue distribution patterns of GnRH I and GnRH II are dissimilar and 
that their expressions are differentially regulated, indicate a distinct role for these 
decapeptides in the body [Cheng and Leung 2005].                                                                                            
 
1.2.2 Function in the central nervous system 
GnRH I is secreted from hypothalamic neurosecretory neurons centered in the arcuate 
nucleus with axons projecting to the median eminence. Its release occurs in response to 
diverse neural inputs operating through neurotransmitters [Samuel and Yen 1975, Fritz and 
Speroff 1982]. GnRH, like many neuropeptides, may act as a neurotransmitter, 
neuromodulator, or local hormone [Hsueh and Schaeffer 1985]. GnRH is assumed to be the 
most important final common mediator of all influences on reproduction conveyed through 
the central nervous system (CNS) [Silverman et al. 1994]. Any abnormalities in GnRH 
synthesis, storage, release or action will result in partial or complete failure of gonadal 
function. Destruction of the GnRH producing neurons in the hypothalamus, or immunization 
against the peptide, prevents gondotrophin function and results in gonadal atrophy [Johnson 
and Everitt 1990]. 
 
The distinguishing feature of GnRH II and its receptors is its wide distribution in extra-
hypothalamic regions of the brain such as the discrete regions of the central and peripheral 
nervous system in areas associated with sexual behaviour. GnRH II is dispersed in brain 
areas where lesions and/or electrical stimulation of these areas have effects on reproductive 
behaviours, such as sexual interest, erection, intromission, thrusting and ejaculation in rats, 
dogs, cats, monkeys and humans [White et al. 1998, Urbanski et al. 1999, Millar 2003]. It is 
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also much more effective than mammalian GnRH in stimulating reproductive behaviour in 
the ringdove [Millar et al. 2001, Millar 2003]. 
 
Molecular variants of GnRH similar to GnRH I, salmon GnRH (sGnRH) and GnRH II, were 
also found in the olfactory bulbs and preoptic-hypothalamic region of the water hog 
(Hydrochaeris hydrochaeris) [Montaner et al. 1998]. Studies in rats showed that GnRH cell 
bodies located in the septal-preoptic-hypothalmic region send only 50-70% of their axons to 
the median eminence. The remaining axons are widely distributed in the brain and some of 
these axons can terminate on other GnRH cell bodies that can be involved in the pulsatile 
release of GnRH. The GnRH neurons migrate from the olfactory placode outside the brain to 
the forebrain during early development. These GnRH neurons are part of the terminal nerve 
and may be the source of the GnRH neurons in the septal-preoptic-hypothalmic area [Pfaff et 
al. 1994, Sherwood et al. 1993].  
 
Reproductive behaviour is affected by olfactory stimuli being transmitted by the terminal 
nerve and the medial olfactory tract in fish and other species that could mediate responses to 
sex pheromones [Pfaff 1973, Moss and McCann 1973]. Sexual behaviour could then be 
directly regulated by GnRH due to GnRH bodies in the nucleus of the midbrain, hindbrain 
and spinal cord of birds, fish, reptiles and amphibians. GnRH also acts on the neurons since it 
promotes mating behaviour in hypophysectomized rats [Pfaff 1973, Moss and McCann 
1973]. The neurons in fish receive input from cells that show GnRH-like immunoreactivity, 
which shifts from the midbrain cell bodies to the terminal regions of the brain to initiate 
courtship [Sherwood et al. 1993]. 
 
 
 
 
 11
Chemical signals play an important role in social communication and these signals have been 
shown to act on physiological mechanisms and behaviour [Schilling et al. 1984]. 
Chemosensory cues stimulate male sexual arousal. The main olfactory system has an 
important role in attracting males to oestrous females, and the vomeronasal receptors are 
important for activating olfactory pathways that engage mating behaviour in a sexually 
dimorphic manner. The GnRH neurons like the vomeronasal organ neurons (VNO) take their 
origin in the olfactory placode and migrate to the basal forebrain along pathfinder axons that 
take their origin in the developing VNO [Keverne 2004]. The vomeronasal organ plays an 
important role in the GnRH system because it transmits chemical signals that activate GnRH 
coordination. The latter induces changes in the olfactory sensitivity to pheromones and, in 
some primates there is a possible link between the vomeronasal function and the number of 
GnRH neurons in the anterior part of the hypothalamus. Lesions of hypothalamic preoptic 
areas in marmoset monkeys and mouse lemurs caused a profound suppression of sexual 
arousal associated with both reduced inter male aggressive interactions [Aujard 1997]. 
Further, the removal of the VNO in the male mouse lemur led to an increase in the number of 
immunoreactive GnRH neurons in the medial preoptic area [Aujard et al. 2005]. The 
importance of the medial preoptic system in sexual behaviour and reproduction was also 
demonstrated in a number of studies on male hamsters’ response to female hamster odours 
and the restoration of mating behaviour after VNO lesions via intra-cerebral GnRH injections 
[Pfeiffer and Johnston 1994, Westberry and Meredith 2003a, Westberry and Meredith 
2003b].  
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The biological function of GnRH II is unknown and only limited attempts have been made to 
describe its regional expression in the primate brain. Previous studies have shown that GnRH 
II is expressed in the mesencephalic cells of non-placental mammalian species. In the brain 
of the tree shrew (Tupaia glis belangeri), a novel mammalian, GnRH II is expressed in the 
neurons of the mesencephalon and was the first nonhypothalamic GnRH isolated from a  
placental animal [Kasten et al. 1996]. It was also shown to be present in the median 
eminence of the hypothalamus of the adult stump tail monkey (Macaca speciosa) and adult, 
as well as foetal Rhesus monkeys (Macaca mulatta). Immunocytochemistry showed that 
there are some cGnRH-like immunopositive cells in the basal hypothalamus and these results 
suggested that GnRH might function as the primary gonadotropin releaser. 
 
GnRH III fibres are expressed in the rat median eminence. GnRH is possibly transported to 
the pituitary by way of the portal system and may interact with pituitary cells. This 
interaction could indicate a role other than the putative function as a neurohormone at the 
hypothalamic-pituitary axis, such as a physiological regulator of reproductive behaviour 
[Yahalom et al. 1999].  However, it is still unclear whether these pituitary cells represent a 
source of GnRH II synthesis or whether they represent a site of GnRH II uptake. It appeared 
that a synthetic GnRH II is a stimulator of gonadotropin release and the investigators 
postulated that an anterior and posterior GnRH system may exist within the brains of recently 
diverged vertebrates, and possibly even in humans. They are: a) the anterior, terminal nerve-
septo-preoptic system, which is the main regulator of gonatropin (LH and FSH) release, and 
b) a posterior system of neurons that express cGnRH II, with fibres projecting throughout the 
brain, including the hindbrain, posterior pituitary, and spinal cord [Lescheid et al. 1997,  
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Montaner et al. 1998]. The later cloning of GnRH cDNA from the Rhesus macaque 
confirmed that both peptides exist in the Rhesus hypothalamus. The high levels of GnRH II 
in the supraoptic nucleus raise the possibility that some of the GnRH II may reach the 
pituitary and peripheral circulation by a different route than GnRH I, which reaches the 
pituitary gland via the hypothalamic portal vessels. Even though GnRH II is expressed in a 
concentrated fashion in at least three distinct regions of the Rhesus hypothalamus, it is not co 
expressed with GnRH I, suggesting unique regulation and function [Urbanski et al. 1999]. 
 
An established function of GnRH II is the inhibition of M currents (K+ channels) through the 
GnRH II receptor in the amphibian sympathetic ganglion. The wide distribution of GnRH II 
in the central and peripheral nervous system suggests that it might act through this 
mechanism as a neuromodulator in the central nervous system [Troskie et al. 1997, Millar et 
al. 2001, Pawson et al. 2003, Millar 2003 and Millar et al. 2004].  
 
1.2.3 Functions in the reproductive system 
1.2.3.1  Mammalian GnRH (GnRH I) 
All vertebrates, from cyclostomes to primates, rely on GnRH for the development and 
maintenance of reproductive functions. GnRH I, synthesized within the cells of the 
hypothalamus, regulates the release of pituitary gonadotrophins, which, in turn, stimulate the 
release of steroid hormones from the gonads [Conn et al. 1986, Kasten et al. 1996, Rama and 
Rao 2001].  
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Even though it was speculated  that two GnRHs in the chicken hypothalamus might assist the 
release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) in avian species, 
GnRH I is suggested to be solely responsible for the secretion of gonadotropic hormones in 
mammals, humans, amphibians and avian species [Miyamoto et al. 1984, Wang et al. 2001]. 
It also plays a role in a variety of other functions such as the direct effects on reproductive 
behaviour and sexual arousal in rodents. Administration of GnRH into the midbrain central 
grey matter facilitates sexual behaviour in rats. Given that the ovarian cycle is regulated by 
gonadotropins, there is evidence that LH secretion facilitates lordosis and mating behaviour 
in ovariectomized female rats [Pfaff 1973, Pfaff et al. 1994, Moss and McCann 1973]. This 
is an indication that mammalian GnRH has behavioural effects not mediated by the pituitary. 
Other stimulants of sexual behaviour have been observed in species of fish, amphibians, 
reptiles and mammals. 
 
Isolation of GnRH I has been reported in various reproductive tissues such as the ovary and 
testis of humans and monkeys, as well as rat ovary [Aten et al. 1987]. Compounds with 
GnRH-like activity were found in the ovaries of the African catfish (Clarias gariepinus) 
[Habibi et al. 1994] and the sea bream (Sparus aurata) [Nabissi et al. 1997]. The addition of 
sGnRH to cultured sea bream oocytes directly stimulated oocyte meiosis and binding sites 
for GnRH  in the ovaries, suggesting that GnRH, or compounds with GnRH-like activity, 
plays an autocrine/paracrine role in the regulation of ovarian function in sea bream and 
catfish. These findings were first shown in a study where GnRH and GnRH agonists were 
used in rat oocytes in vitro [Hillensjö and LeMaire 1980]. If there is a requirement for GnRH 
at stages just before ovulation, as in the trout [Von Schalburg et al. 1999], then caution 
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should be taken in interpreting the results from rats. A number of effects have been reported 
when gonodal cells were exposed to GnRH in vitro. However, these effects may not be 
physiological if the rat gonad does not express GnRH peptide in vivo at that specific stage of 
development. 
 
The expression of GnRH in reproductive tissues may modulate various processes or 
mechanisms during the fertilization process. The presence of GnRH and GnRH receptors has 
been shown to play a role during spermatogenesis, sperm maturation, and fertilization 
[Morales and Llanos 1996] such as the increase of sperm binding to the ovum, an effect that 
is inhibited by GnRH antagonists [Morales et al. 1994, Morales 1998, Morales et al. 1999]. 
Immunoreactive GnRH in human reproductive tissue, such as ovary, granulosa-luteal cells, 
mammary gland and testis, along with the low expression of the gene, suggests that the 
peptide may be synthesized for functioning locally as an autocrine or paracrine factor [Dong 
et al. 1993, Peng et al. 1994]. In cultured rat granulosa cells, GnRH induces apoptosis and 
can thus be involved in the process of follicular atresia. GnRH may also play a role in follicle 
rupture and oocyte maturation during the pre ovulatory period in the rat. In human granulosa 
luteal cells, GnRH I and II, may play a role in regulating luteolysis during the luteal phase of 
the menstrual cycle [Samuel and Yen 1975, Fritz and Speroff 1982] and might promote 
apoptosis as has been shown for rats [Khosravi and Leung 2003]. In the human placenta, 
GnRH functions as a local regulator, where GnRH or GnRH-like peptides are synthesized by 
cytotrophoblasts and syncytiotrophoblasts during embryogenesis. It also initiates the 
secretion of human chorionic gonadotropin (hCG), which in turn stimulates the synthesis and 
secretion of progesterone from the corpus luteum [Rama and Rao 2001]. This suggests that 
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the action of GnRH is mediated through its typical high affinity receptor [Kakar and Jennes 
1995] and that the placenta might possess its own GnRH system, analogues to the 
hypothalamus-pituitary system [Cheng et al. 2001].  
 
Pubertal development in mammals results from a complex cascade and progressive 
maturational events involving the entire gonodal axis. The appropriate expression of the 
receptor in gonadotrophs is critical for GnRH signalling and hence for gonadotropin 
secretion and sexual development [Samuel and Yen 1975]. The importance of GnRH for 
sexual development was shown by the strong induction of the gene and its receptor during 
the infantile period followed by a weaker persistent activation during puberty in the female 
rat [Zapatero-Caballero et al. 2004]. 
 
1.2.3.2  Chicken GnRH (GnRH II) 
As with GnRH I, GnRH II is found in reproductive tissue such as in baboon ovary where it 
has been proposed to act as a potent regulator of ovarian function and hormone regulation 
during pregnancy. Like type I, GnRH II is also capable of inducing apoptosis in the human 
ovary [Siler-Khodr et al. 2003, Khosravi and Leung 2003].  
 
Previous studies have shown that synthetic GnRH II is a potent stimulator of gonadotropin 
release in Rhesus macaques in vivo [Lescheid et al. 1997]. It is likely that GnRH I and GnRH 
II receive a distinct set of inputs since they use two different routes to reach the pituitary and 
thus together may control steroidogenesis, sperm production, follicular development and 
ovulation [Urbanski et al. 1999]. The expression of GnRH II in the testis, epididymis, 
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seminal vesicle and baboon fallopian tubes further suggests that this peptide may play a role 
in sperm development and in tubal function [Siler-Khodr et al. 2003]. 
 
 GnRH II has less than one-tenth or one-third the LH-releasing activity of GnRH I in rat and 
sheep pituitaries in vitro [Miyamoto et al. 1984] and no effect of a GnRH analogue could be 
observed on baboon pituitary LH release [Siler-Khodr et al. 2003]. On the other hand, there 
have been reports of an increase in LH concentration after GnRH II was administered 
systemically during the luteal phase to Rhesus monkeys, but with little effect on LH 
concentration in the follicular phase [Lescheid et al. 1997, Densmore and Urbanski 2003]. 
Results of pituitary cell culture studies from male Rhesus monkeys supported previous 
findings that GnRH II stimulates LH and FSH release from the pituitary cells by activating 
GnRH I receptors [Okada et al. 2003]. Recently, some specific FSH-releasing factors, such 
as sGnRH II and lamprey GnRH III, have been reported. Thus, GnRH II possibly functions 
as a specific stimulator for FSH [Millar et al. 2004].  
 
GnRH II has a potent effect on the inhibition of progesterone production in the ovary and 
hCG release in the placenta. The high affinity binding sites for GnRH II in baboon ovary and 
human placenta suggest a possible role of paracrine activity in extra-hypothalamic tissues. 
The specific binding sites and action of GnRH II and its analogues in reproductive tissues 
and reproductive cells such as the ovary, ovum, male reproductive tract, sperm, fallopian 
tube, endometrium, and/or trophoblast, support the possibility of GnRH II being a regulator 
of the reproductive system [Siler-Khodr et al. 2004]. 
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1.3 GnRH and its seven structural forms 
Seven forms of non-mammalian GnRH distinct from mammalian GnRH (GnRH I) have been 
identified. The different forms of GnRH belong to a family of peptides that are structurally 
related. 
 
All the GnRH structures are decapeptides with at least 50% to 90% sequence identity. The 
length of the GnRH and five of the amino acids have been conserved. The seven GnRHs, 
with their distinct primary structures, are named after the animals from which they were first 
isolated by peptide chemistry. In addition, the primary structure of GnRH for at least one 
representative species for each vertebrate class has been determined for Agnatha or jawless 
fish (Lamprey),  Chondrichthyes or cartilaginous fish (shark), ratfish, Osteichthyes or bony 
fish (salmon), catfish (Ngamvongchon), Amphibia (frog), Reptilia (Alligator), Aves 
(chicken) and Mammalia (pig and sheep)  [Sherwood et al. 1993]. 
  
The GnRH family does not appear to be limited to only seven non-mammalian members and 
it is generally accepted that different forms of GnRH have arisen through gene duplication 
from a single ancestral GnRH form whose origin pre-dates vertebrates [Sherwood et al. 
1993]. Data on the appearance of different forms in one species, such as the three different 
forms expressed in teleost fish and the basal salmonid, are crucial in understanding the 
evolution of multiple forms of GnRH within individuals [White et al. 1995, Adams et al. 
2002]. 
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Various studies have shown other GnRHs with distinct structures and to date, 23 GnRH 
forms or GnRH-like sequences have been identified in various non-mammalian vertebrates. 
In most vertebrate species, GnRH I or GnRH II is present suggesting early gene duplication. 
Both peptides are distributed in a wide range of tissues in vertebrates [Sealfon et al. 1997, 
Sherwood et al. 1993] and apparently have diverse functions.  These include neuroendocrine, 
paracrine and autocrine neuro- modulatory roles in the central and peripheral nervous system 
[Millar et al. 2001, Millar 2003, Millar et al. 2004, Cheng and Leung 2005]. 
 
1.4 Conservation of GnRH structures in vertebrates 
The mammalian gonadotropin-releasing hormone (GnRH I) was the first isoform of GnRH 
that was identified in mammals with the linear sequence of (pGlu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly-NH²). It is found in humans and has a wide distribution in vertebrate species 
[Seeburg and Adelman 1984, White et al. 1998]. All forms of GnRH identified to date have 
10 amino acids with a pyroglutamic acid N terminus and an amidated glycine C terminus. 
Amino acids 1 through 4 are tightly conserved except for position 2 in guinea pig (gp) GnRH 
and position 3 in lamprey (l) GnRH I; the conservation may reflect the importance of 
residues 1 through 3 for the functional release of LH and FSH. Variations in GnRH peptide 
structure are typically the result of different amino acids in positions 5 to 8. The structure of 
the peptide remained unchanged. The conservation of this structure reflects the importance of 
the peptide for reproductive success [Adams et al. 2002, Millar et al. 2004]. 
 
Of all the structural variants of gonadotropin-releasing hormone, GnRH II (cGnRH) is 
remarkably conserved without any sequence substitutions among vertebrates. It is regarded 
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as the most ancient and conserved member of the GnRH family, because it has been found in 
representative members of every vertebrate class [Sherwood et al. 1993]. GnRH II is present 
in all jawed vertebrates, except jawless fish, and is conserved from bony fish to humans 
indicating that this is probably the earliest evolved form of GnRH that remained unchanged 
for at least 500 million years. It was first cloned and sequenced from the chicken 
hypothalamus (cGnRH II) with an amino acid sequence of pGlu-His-Trp-Ser-His-Gly-Trp-
Tyr-Pro-Gly-NH2 [Kasten et al. 1996, White et al. 1998 and Urbanski et al. 1999]. It differs 
from GnRH I by having His5, Trp7 and Tyr8 residues [Miyamoto et al. 1984, Sealfon et al. 
1997, Densmore and Urbanski 2003, Ikemoto and Park 2003, Cheng and Leung 2005].  
 
In many vertebrate species, a third conserved form of GnRH (salmon GnRH) was found in 
teleost fish and is designated GnRH III. Even though the origin of GnRH-III is less clear, it 
seems that the gene duplication only occurred recently and originated after the divergence of 
teleosts from the vertebrate lineage [Sherwood et al. 1993, White et al. 1998, Yahalom et al. 
1999 and Millar et al. 2004].   
 
1.5 Molecular biology of GnRH 
1.5.1 GnRH gene and GnRH-associated peptide (GAP) 
It is widely recognized that the structure of all known vertebrate GnRH genes is conserved 
and is composed of four exons and three introns. The first exon encodes the 5’-untranslated 
region (UTR) and consists of 61 bp in mRNA expressed in the hypothalamus. The second 
exon encodes the signal sequence, the GnRH decapeptide, the GKR processing signal and the 
first 11 GAP residues. The third exon encodes GAP amino acids 12-43 and the fourth exon 
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encodes the remaining GAP residues and contains the translation termination codon, as well 
as the entire 3’UTR [Sherwood et al. 1993, Sealfon et al. 1997]. 
 
The GnRH I gene is derived from a larger, precursor molecule called pre-pro-GnRH. This 
molecule comprises the decapeptide GnRH preceded by a signal sequence of 23 amino acids 
and is followed by a Gly-Lys-Arg sequence necessary for enzymatic processing and C-
terminal amidation of GnRH. The C-terminal region of the precursor is occupied by a further 
56 amino acids that constitute the so-called GnRH associated peptide or GAP. GAP has been 
shown to release LH and FSH equipotentially from the anterior pituitary. In all species 
examined, immunocytochemical techniques have located the GnRH precursor, together with 
GAP and GnRH itself, in a major group of neurons within the medial preoptic area and 
adjacent anterior hypothalamus [Johnson and Everitt 1990, Dong et al. 1996]. 
 
The length of GnRH remained at 10 amino acids, the amino (pGlu) and carboxyl (Gly-
amide) residues are unchanged, and five of the 10 residues are identical from lamprey to 
human. The most stable region of the peptide, residues 1-3, is responsible for releasing 
gonadotropins, while the region with the most changes, 5-8, is thought to mediate receptor 
binding [Sealfon et al. 1997]. 
 
Two forms of GnRH, termed GnRH I and GnRH II, encoded by separate genes have been 
identified in humans. Although they share comparable cDNA and genomic structures, their 
tissue distribution and regulation of gene expression are significantly dissimilar. Humans 
may be unusual with respect to GnRH control of reproductive endocrinology in that they 
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possesses another gene encoding GnRH-II located on chromosome  8p11-p21 and 20p13 , 
distinct from the GnRH I precursor gene that is encoded within the genome, on chromosome 
4 [White et al. 1998, Pawson et al. 2003]. The pre-pro-GnRH II gene consists of a 5’-
untranslated exon and three coding exons, with the mature peptide encoded within coding 
exon 1 [White et al. 1998]. It has also recently been found in the reptilian species, the leopard 
gecko (Eublepharis macularis). The genomic structure consists of four exons and three 
introns [Ikemoto and Park 2003]. 
 
However, the GnRH II gene (2.1kb) is shorter than the GnRH I gene (5 kb) because introns 2 
and 3 of GnRH I are much larger. Although the corresponding precursor proteins are quite 
similar in length, the GAP is 50% longer in the GnRH II precursor, suggesting that a 
relatively larger GAP may be a common characteristic among mammalian GnRH II 
precursors [Cheng and Leung 2005].  
 
1.5.2 Regulation of the GnRH gene 
The mammalian GnRH gene appears to have different transcriptional start sites depending on 
the species. Changes in the organization of the 5’-flanking region and in the regulation of 
gene expression by specific transcription factors should elucidate functional changes in the 
regulation of reproduction during evolution [Sherwood et al. 1993]. In humans, transcription 
of the gonadotropin-releasing hormone (GnRH) gene can be initiated at two transcription 
start sites to produce different GnRH mRNAs. The upstream transcription start site is used 
only in non-hypothalamic reproductive tissues and tumours. In the hypothalamus, the 
transcription start site utilized is located 61 base pairs upstream of the first exon/intron 
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junction. However, in many reproductive tissues a second start site 579 bases upstream of the 
hypothalamic start site is also utilized. RT-PCR analysis of the first strand cDNA derived 
from RNA isolated from human placenta, mammary gland, testis and ovary showed that the 
upstream pro-GnRH gene transcription site was preferentially used in these tissues. GnRH 
transcripts were detected in the rat ovary and the major transcription start site is located 
downstream of primer 11 [Goubau et al. 1992]. The rat and mouse pro-GnRH gene promoter 
regions are very different from those in the human in the 579 region, and they are lacking the 
upstream transcription start site [Dong et al. 1993]. To determine if a similar pattern of 
GnRH gene expression exists in non-human primates, a GnRH cDNA was cloned from 
Rhesus monkey hypothalamic RNA by using PCR to show a 96% similarity between 
monkey and human, with 94% similarity in the upstream promoter region. An upstream 
transcription site was also identified in Cynomolgus monkey testicular mRNA, which was 
different from the human GnRH gene. However, this proved that the GnRH gene expression 
pattern in this monkey is similar to that seen in the human and differs markedly from that in 
rodents. A reproductive tissue-specific transcriptional start site was located 504 bases 
upstream from the hypothalamic start site in the monkey testis, placenta, ovary and 
mammary gland. As with the human GnRH gene, two transcription start sites were used in 
transcribing the monkey GnRH gene. Because of the multiple transcription sites for the 
GnRH gene found in Rhesus and Cynomolgus monkeys, non-human primates make excellent 
models for studying GnRH gene regulation [Dong et al. 1996].  
 
Some studies have shown that both estradiol and cortisol may be involved in regulation of 
GnRH gene expression in the human placenta. Based on some results, it is suggested that the 
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paracrine and autocrine regulation of hCG secretion by placental GnRH is mediated through 
the regulation of gonadotropin-releasing-hormone receptor (GnRHR) message. GnRHR gene 
expression was shown to be up regulated by GnRH, but down regulated by hCG [Peng et al. 
1994, Khosravi and Leung 2003]. It is hypothesized that gonadal steroids may regulate 
GnRH I and II. The presence of the progesterone response element (PRE) in the 5’flanking 
region of the human GnRH receptor, suggests the possible regulation of this gene by 
progesterone at the placental expression [Cheng et al. 2001, An et al. 2005].   
 
1.5.3 GnRH Agonists and Antagonists 
Recent advances in biochemical techniques have made it possible to synthesize a new 
peptide once the structure is known. Forms that are structurally altered are called analogues 
and some synthetic analogues are many times more potent than the naturally occurring 
hormone and prove very useful in both experimental and clinical work. Inhibitory analogues 
block actions of the natural hormone by binding to the same receptor but not effecting the 
anticipated actions [Norris 1985]. 
 
Studies in receptor binding have shown that certain GnRH analogues that are antagonists of 
mammalian receptors behave as agonists in Xenopus laevis and chicken receptors, and since 
new generation peptide and non-peptide antagonists are being sought, this phenomenon 
provides the opportunity to elucidate interactions and the mechanism underlying receptor 
activation [Ott et al. 2002].  
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GnRH and its analogues have led to exciting new avenues of therapy in virtually every 
subspecialty of internal medicine, as well as in gynaecology, paediatrics, urology and 
oncology. The hypothalamic-pituitary-gonodal axis can be influenced in two distinct classes 
of therapeutic applications. The first application provides a natural sequence of GnRH in a 
pulsatile fashion via a portable infusion pump to mimic the normal physiology of 
hypothalamic secretion, and the second mode uses long-acting GnRH agonists administered 
in a depot delivery to produce a paradoxical desensitization of pituitary gonadotropin 
secretion. 
 
This biochemical castration induced by GnRH agonist administration is a safe, effective, 
complete and reversible method of removing the overlay of gonadal steroids from a variety 
of diseases that they are known to exacerbate. This is also an ideal management tool to 
control population size in wild or captive animals without any negative side effects [Conn 
and Crowley 1994]. When the GnRH receptor is exposed to high concentrations of agonist, it 
becomes down regulated and results in the suppression of LH and FSH secretion. This led to 
the widespread use of GnRH analogues for the treatment of a number of endocrine-related 
disorders or hormone dependent diseases such as endometriosis and prostatic cancers [Eidne 
et al. 1992]. The presence of GnRH-like peptide in prostatic cancer cells may contribute to 
the appearance or promotion of cancer [Fekete et al. 1989] and at the same time lead to the 
possible role of direct anti-proliferative effect of GnRH analogues on prostatic tissue [Quyam 
et al. 1990, Azad et al. 1993]. Triptorelin, a GnRH agonist, has been shown to exert a double 
inhibitory-stimulatory action on cell growth when tested on two prostatic cell lines depending 
on the dose and environmental conditions [Ravenna et al. 2000]. 
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In the rat and mouse, mammary tumours regress after administration of GnRH. Human 
patients with breast, prostate and pancreatic tumours have also shown clinical improvement 
after GnRH analogue treatment [Bützow et al. 1987]. An exogenous GnRH analogue 
addition to culture medium has been shown to inhibit growth of cultured mammary 
carcinoma cells (MCF-7) [Bützow et al. 1987] and the proliferation of cancer cells [Emons et 
al. 1989, Kakar and Jennes 1995]. 
 
Another study supported the previous findings that the GnRH agonist Triptorelin inhibits the 
proliferation of endometrial cancer cells, epithelial ovarian cancer cells and estrogen-
stimulated breast cancer cells [Ravenna et al. 2000, Ciocca et al. 1990 and Emons et al. 
2000]. The incorporation of [³H] thymidine to tumour cells in culture suggested the tumour 
suppressing effect of GnRH agonists and antagonists may be a direct effect of GnRH on cell 
growth mediated through its high affinity receptors [Kakar et al. 1994, Kakar and Jennes 
1995].  
 
The effects of GnRH agonists on various reproductive functions have been investigated. 
Administration of GnRH or its potent agonist results in sustained increases in serum 
gonadotropins and treatment with high doses has been seen as a potential means of enhancing 
fertility. In female rats, long-term administration of pharmacological doses of GnRH or 
agonist inhibits ovarian steroidogenesis, ovulation, ovum transport, ovum implantation, 
pregnancy and uterine growth. It also exerts an extra pituitary action, as shown by their 
ability to inhibit ovarian function by decreasing ovarian oestrogen production [Hsueh and 
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Erickson 1979]. GnRH and its analogues have also been used extensively to induce ovulation 
and spawning in farmed fish [Pagelson and Zohar 1992].  
 
The GnRH I analogue, Buserelin, caused suppression of progesterone production from 
Baboon granulosa cells in vitro [Siler-Khodr et al. 2003]. The analogue had no effect on 
pituitary release after long-term exposure, which may indicate pituitary specificity for 
mammalian GnRH. Specific GnRH II analogues may be useful for the site-specific 
regulation of ovarian function and may have a limited effect on pituitary function. In another 
study using Buserelin, the dependency of Ca²+ -dependent CI channels by Xenopus oocytes 
injected with rat pituitary mRNA was shown by measuring the responses of the oocytes to 
this analogue [Yoshida et al. 1989]. 
 
GnRH II analogues also demonstrated their role as a contraceptive agent when administered 
chronically around the time of ovulation or early luteal development in the Rhesus monkey. 
These GnRH II analogues may serve as an effective, non-steroidal, postcoital contraceptive 
[Siler-Khodr et al. 2004]. 
 
Continuous GnRH agonist treatment suppresses the pituitary-testicular axis in a wide range 
of species. This suppression is characterized by a decline in the peripheral concentrations of 
LH and testosterone, and regression of the testis, with eventual induction of azoospermia. In 
male rats, the agonists inhibit testicular steroidogenesis, spermatogenesis and male accessory 
sex organ growth [Hsueh and Erickson 1979, Hsueh and Jones 1983, Hsueh and Schaeffer 
1985]. In monkeys, the acute and chronic administration of gondotropin-releasing hormone 
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antagonists and agonists can result in a decrease in testicular volumes, ejaculate volumes and 
sperm production [Bint Akhtar et al. 1985, Weinbauer et al. 1987a, Weinbauer et al. 1987b, 
Mann et al. 1987, Rao et al. 1990] 
 
Antide, a highly selective GnRH I antagonist that blocks gonadotropin secretion, was used to 
show that GnRH II stimulates LH and FSH secretion in vivo (Rhesus monkey), as well as in 
vitro (monkey pituitary cells), and that this action occurs through the GnRH I receptor 
[Densmore and Urbanski 2003, Okada et al. 2003]. Antide also disrupted the normal oestrous 
cycle in an application of the antagonist in the preoptic area of female rats. This antagonist 
was shown to be a potential contraceptive in the marmoset, without affecting the postnatal 
rise in testosterone in the male infants [Fraser et al. 1994] as well as in Cynomolgus monkeys 
by suppressing gonadotrophins for 40-50 days [Conn and Crowley 1994].  
 
In a number of species, however, males appear to be insensitive to the inhibitory effects of 
GnRH agonists. A male marsupial, Macropus eugenii, maintained a tonic LH secretion and 
appears to be resistant to the contraceptive effects of the chronic GnRH agonist, Deslorelin, 
treatment [Herbert et al. 2004]. 
 
In two separate studies on sexual development, the GnRH antagonist, Cetrorelix, was used to 
block the effect of endogenous GnRH action. These results showed that the sexual 
development of male and female rats is accompanied by the expression of the GnRH receptor 
and gonadotropin subunit genes during pubertal development [Zapatero-Caballero et al. 
2003, Zapatero-Caballero et al. 2004]. Cetrorelix has also been shown to block GnRH I but 
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not GnRH II. These effects might be mediated via a GnRH II-specific receptor since 
antagonists bind to receptors at sites that are distinct from those occupied by agonists 
[Pawson et al. 2003]. 
 
The increased biologic activity of GnRH agonists is due to their ability to stay bound to the 
pituitary receptor longer than the natural hormone and to their capacity to resist enzyme 
degradation. The half-life of the GnRH analogues in circulation is identical to that of the 
natural hormone and therefore does not contribute to their increased biologic activity 
[Densmore and Urbanski 2003]. 
 
1.6 GnRH Receptors 
The interaction between GnRH and its receptor is a critical event in the endocrine regulation 
of reproduction and therefore, understanding the regulation of the receptor is important for 
the study of normal reproductive physiology. The pituitary GnRH receptor is primarily 
located in the plasma membrane of gonatrophs and it is evident that almost all 
neurotransmitters and neuropeptides have more than one receptor. It is thus hard to conceive 
that three GnRH isoforms that are 70%-80% homologous to each other would share a 
common, single GnRH receptor. However, cross-activity of these isoforms with the GnRH I 
receptor has been suggested [Yahalom et al. 1999]. Amphibia, like most vertebrates, have 
two forms of GnRH and a receptor for chicken GnRH II has been identified in the 
sympathetic ganglion of the  bullfrog  (Rana catesbeiana) and platana  (Xenopus laevis) 
[Troskie et al. 1997]. The presence of at least two GnRHs in a particular species led to the 
concept of the existence of more than two types of receptors, suggesting that the duplication 
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of the GnRH gene was accompanied by a coordinated structural evolution of the cognate 
receptors. The cloning of two subtypes of receptors with differential distribution in the brain 
and pituitary of the goldfish (Carassisius auratus) [Illing et al. 1999] and three subtype 
receptors in the pituitary and hindbrain of the bullfrog, confirmed this theory [Wang et al. 
2001]. 
 
The GnRH I receptor is an established member of the Ca²+-dependant family that is 
expressed on the surface of pituitary gonadotrope cells [Conn 1986, Conn et al. 1986, 
Stojilkovic et al. 1994]. The predicted amino acid sequence for the receptor has more than 
80% overall arrangement identity in mammals and is highly conserved with the putative TM 
domains. It belongs to the group of the rhodopsin-like G protein-coupled receptor (GPCR) 
family that is characterized by seven-transmembrane (7TM) domains connected by 
alternating intra cellular and extra cellular loop (EL) domains [Kakar et al. 1992, Huckle and 
Conn 1988, Sealfon et al. 1997, Illing et al. 1999, Cui et al. 2000]. The extra cellular loop 2 
of the receptor has been identified as the determinant for agonist activity [Ott et al. 2002]. A 
unique feature of the mammalian receptor I is the absence of the cytoplasmic carboxyl-
terminal tail [Eidne et al. 1992, Kakar et al. 1992, Sealfon et al. 1997]. 
 
The GnRH I receptor was first cloned from mouse and several other mammalian species 
[Eidne et al. 1992] and homologous receptors were soon identified in the human [Kakar et al. 
1992, Chi et al. 1993, Fan et al. 1995, Millar et al. 1999].   
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There is a high degree of homology between cloned GnRHR, particularly between mice and 
rats, in which 93% of the amino acid sequences are conserved, while the receptor from the 
pituitary of the rat shows the same homology to that of human receptors [Eidne et al. 1992]. 
The sequencing of receptors from a number of fish such as the GnRH receptors found in the 
pituitary of the Gilthead Sea bream (Sparus aurata) enabled researchers to study the 
contribution of receptor affinity in the determination of relative biopotencies of GnRH 
analogues [Pagelson and Zohar 1992].  
 
The GnRH II ligand structure is conserved from bony fish to humans, indicating that this is 
probably the earliest evolved form of GnRH and thus has critical and specific functions. The 
cow, sheep and human receptors are 328 amino acids long, while the mouse and rat receptors 
are 327 amino acids, due to the absence of a residue in the second extra cellular domain. In 
type II receptors, the N-terminal domain is two residues longer and more negatively charged 
than that of the type I receptors. Extra cellular loops two and three are also shorter in the type 
II receptor [Pawson et al. 2003]. The catfish receptor is 370 amino acids in length and 
together with the GnRH II receptor and those found in the goldfish, retained a 56-residue 
cytoplasmic tail domain at the carboxyl-terminus that is phosphorylated in response to GnRH 
II binding. This leads to receptor internalization and desensitization along with the coupling 
of both receptors to the G coupled-protein to mediate the intracellular production of inositol 
phosphates [Kakar et al. 1992, Cui et al. 2000]. 
 
The tail sequence is not conserved between mammalian and amphibian homologues [Illing et 
al. 1999, Neill 2002, Stojilkovic et al. 1994 and Pawson et al. 2003]. The importance of the 
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tail for rapid agonist-induced internalization has been demonstrated in studies for the 
marmoset type II and the chicken GnRH receptor, while the carboxyl-terminal tail of the 
catfish GnRH receptor proved to be important for cell surface expression, ligand binding, and 
receptor phosphorylation and internalization [Millar et al. 2001, Pawson et al. 2003, Millar et 
al. 2004]. 
 
GnRH regulates reproduction via the well-characterized mammalian pituitary GnRH I 
receptor. This action was confirmed in an in vitro and in vivo study where results showed that 
GnRH II stimulated LH and FSH release by activating GnRH I receptors [Okada et al. 2003, 
Densmore and Urbanski 2003]. Three GnRH receptors or receptor-like genes were identified 
in the human genome: 
1) the well established GnRH I receptor gene located on chromosome 4 
2) an apparent GnRH II receptor gene located on chromosome 1, and 
3) a sterile GnRH II receptor-like homolog gene on chromosome 14 [Kakar et al. 1992, Neill 
2002, van Biljon et al. 2002].  
 
The chromosome 1 gene is comprised of exons 1, 2 and 3, whereas the chromosome 14 gene 
is comprised of only exons 2 and 3 of the putative receptor. The transcripts for chromosome 
1 are either not expressed or only expressed in low levels, but exon 2-3 amplicons for 
chromosome 14 are abundant at high levels [Neill et al. 2001, Neill 2002, van Biljon et al. 
2002]. A study using an exon 1-specific probe for chromosome 14 was found with relatively 
strong signals in putamen, occipital lobe, cerebellum, caudate nucleus, heart and testis 
[Millar et al. 2001, van Biljon et al. 2002]. To facilitate the identification and 
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characterization of selective non-peptide GnRH antagonists, the GnRH I receptor in the dog 
was cloned and is 92% identical to the human GnRH receptor [Cui et al. 2000, Millar et al. 
2004]. 
 
An immunohistochemical assay confirmed the presence of a GnRH receptor in the human 
pituitary that was localized on the surface of the anterior pituitary cells co-localizing with 
FSH [Lee et al. 2000] and a highly selective type II receptor has been cloned and identified 
in the monkey brain. The receptor was cloned from the pituitary of the Bonnet monkey 
[Santra et al. 2000], a receptor specific for GnRH II  from the Rhesus monkey pituitary, a 
kidney-derived cell line from African green monkeys, [Neill et al. 2001] and from the 
pituitary of  the marmoset [Millar et al. 2001], but its physiological function remains 
unknown. All three receptors revealed that they code for a typical seven TM domain GPCR. 
The primary amino acid sequence of the Marmoset type II GnRH receptor has 39% identity 
with the type I receptor. The mRNAs of all mammalian GnRH receptors cloned to date are 
encoded by three exons, and the gene structures are conserved. Type II receptors are 
expressed in the anterior pituitary of several mammalian species and throughout the brain, as 
shown in Marmoset and human brains. The type II receptor is more widely distributed than 
type I and this includes areas in the brain associated with sexual arousal. It might even have a 
unique function in the monkey brain and pituitary other than the regulation of gondadotropin 
secretion. The pharmacological characterization revealed that the Marmoset type II receptor 
is highly selective for GnRH II and less so for GnRH I. Two other GnRHs reportedly 
expressed in mammals are also active with the type II receptor [Sealfon et al. 1997, Neill et 
al. 2001, Neill 2002 and Millar et al. 2001]. Furthermore, the marmoset type II receptor can 
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be activated by a GnRH I antagonist, which is a full antagonist of the human type I receptor. 
This observation may help explain why certain GnRH I antagonist exhibit agonistic activities 
in some gynaecological cancer cells expressing the type II receptor [Millar et al. 2001]. 
 
Using reverse transcript polymerase chain reaction and Southern blot analyses, expression of 
GnRH I receptor mRNA indistinguishable from its pituitary counterpart has been 
demonstrated in various ovarian compartments such as the human ovaries and human 
granulosa-luteal (GL) cells [Kakar et al. 1992, Peng et al. 1994]. In human GL cells, 
treatment with hCG for 24 hours induces a dose-dependent inhibition of GnRH receptor 
mRNA levels [Kakar and Jennes 1995]. Even though binding sites for GnRH were detected 
in the human placenta, no receptor could be found. The failure to amplify the placental 
GnRH receptor mRNA consistently at all stages of gestation, using the same set of primers, 
suggests that there might be different receptors expressed at different stages of gestation 
[Rama and Rao 2001]. Human GnRH receptor gene expression is regulated by progesterone 
at pituitary and placental levels [Cheng et al. 2001]. This effect of progesterone was also 
shown in vitro, using a human neuronal medulloblastoma cell line (TE671) [An et al. 2005]. 
 
GnRH receptors are expressed in Leydig cells but not the Sertoli cells [Kakar et al. 1992] and 
are also found in both mouse and rat testicular germ cells, even though there was not 
conclusive evidence for the presence of a receptor in mature sperm cells. These results 
demonstrated that the receptor may interact in testicular germ cells with GnRH or GnRH- 
like peptides produced in the testis and may be part of a paracrine system [Bull et al. 2000]. 
An immunohistochemical assay using antibodies revealed the presence of a GnRH receptor 
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in human sperm that is mainly localized in the acrosomal region [Lee et al. 2000]. This could 
explain the responsiveness of human sperm to GnRH in enhancing sperm-zona binding 
shown in a previous study [Morales 1998].  
 
The confirmed presence of a type II GnRH receptor immunoreactivity in human tissue led to 
the search for evidence that the homologous gene for receptor II located on chromosome 1 in 
humans might be functional. These investigators cloned a potentially full-length type II 
GnRH receptor transcript from the gene on chromosome I in human sperm. It showed the 
presence of a UGA translation stop codon within exon 2, as well as a frame shift within exon 
1 compared to the recently cloned Vervet monkey type II receptor that contains a CGA 
arginine codon [Neill et al. 2001]. 
 
The in situ localization of type II GnRH receptor transcripts to the ad luminal region of the 
seminiferous epithelium is consistent with the distribution of other haploid-specific mRNAs 
and suggests that this receptor is post-meiotically expressed in round and elongated 
spermatids [Wykes et al. 1997]. These transcripts are distributed throughout the entire sperm 
head. Differentiating spermatids might require a functional type II GnRH receptor at specific 
stages during spermatogenesis [Willson and Ashworth 1987]. Sperm have also been shown 
to express receptors for other hormones or signalling molecules such as the oestrogen 
receptor and A1 adenosine receptor [Wassarman 1990, Durkee et al. 1998 and Minelli et al. 
2000]. Whether a full length GnRH II receptor protein is expressed in mature sperm and 
whether the transcripts found are functional, still need to be clarified [van Biljon et al. 2002]. 
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A full-length human type II receptor from testis was reported with the presence of a frame 
shift and a stop codon [Neill et al. 2001, Neill 2002].  
 
mRNA contains a stop codon and it seems likely that the gene is a transcribed pseudo gene 
although it seems functional in primates. This may reflect the involvement of the type II 
GnRH receptor in the induction of mating behaviour of other primates that are seasonal 
breeders, unlike humans [Neill et al. 2001]. 
 
Some observations seemed to indicate that GnRH receptor expression is significantly 
elevated when human tissue becomes cancerous or is in an abnormal or diseased state. 
Several studies support the concept that about 50% of breast and approximately 80% of 
ovarian and endometrial cancers express GnRH I receptors. They are found in other 
tumorous tissues and  cancer cell lines [Emons et al. 1989, Kakar and Jennes 1995, Emons et 
al. 1998],  are absent in normal breast and liver cells, and are present in low levels in normal 
heart and brain tissue [Lee et al. 2000]. The type I receptor is effective in inhibiting the 
proliferation of tumour cells due to its resistance to densitization, a common and rapid event 
of the GPCR super family and undergoes very slow internalization compared to the type II 
receptor. The GnRH I receptor remains active at the cell surface for longer than most other 
GPCRs [Pawson et al. 2003]. Another study suggests that the inhibitory and stimulatory 
effects of GnRH on cell proliferation, using four cell lines, exhibit distinct different patterns 
of ligand sensitivity and that these effects occur via different types of GnRH receptors. For 
the first time these results proved that the human type II receptor could be functional 
[Enomoto et al. 2004]. 
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Recent cloning of the gonodotropin-releasing hormone (GnRH) receptor from the human 
breast tumour cell line (MCF-7), and from an ovarian tumour, and its expression in various 
other human tumours, tumour cell lines and reproductive organs, have been reported [Bützow 
et al. 1987]. An ovarian cancer cell line shown to be type II receptor mRNA positive, but 
type I receptor mRNA negative, responded only to GnRH II but not GnRH I.  
 
Results have also shown that the GnRH receptors in human extra-hypophysial tissues, such 
as breast and ovarian tumours, have the same high binding affinities commonly associated 
with the GnRH receptor of the pituitary gland and that the nucleotide sequences are the same 
[Kakar et al. 1994, Emons et al. 2000]. In rats, high affinity and low capacity receptors have 
been demonstrated in the ovaries comparable to pituitary GnRH receptors [Hsueh and 
Schaeffer 1985] but reports for GnRH I receptors in human prostate cancer and  prostatic cell 
lines have shown that  the affinity of these sites is generally lower than that of the pituitary 
receptor [Ravenna et al. 2000]. The receptors for LHRH (GnRH), Somatostatin and Prolactin  
in human and rat prostate cancers suggest that LHRH (GnRH), along with other hormones, 
may act as a growth or transforming factor that contributes to the promotion of prostate 
cancer in humans [Fekete et al. 1989].  
 
Several sources indicate that the expression of extra-pituitary GnRH receptor is not limited to 
reproductive tissues only. It has been demonstrated by RT-PCR and Southern blot 
hybridization that the type I receptor is also expressed in the liver, heart and kidney [Kakar 
and Jennes 1995], whereas the type II receptor mRNA is expressed in human heart, pancreas 
and skeletal muscle [Millar et al. 2001]. 
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The sexual development of female and male rats is accompanied by a progressive and 
concerted expression of the GnRH receptor but gonadotropin subunit genes in the anterior 
pituitary reach maximal rates during infancy and are kept at a minimum during juvenile 
prepubertal development [Zapatero-Caballero et al. 2003, Zapatero-Caballero et al. 2004]. 
 
In humans, it seems as if the type II receptor has become non-functional and that its function 
is now served by the type I receptor as the target for GnRH II. The type II receptor also 
appears to be silenced in the mouse, chimp, cow and rat genomes. GnRH II receptor 
immunoreactivity in the human pituitary and brain [Miller et al. 2001] and the wide 
expression of the type II GnRH, suggest that a functional GnRH II receptor exists and that 
the gene on chromosome 1 is not a pseudo gene [Neill 2002, Millar 2003, Neill et al. 2004]. 
However, the reports on the disruption of the human type II receptor gene by a frame shift 
and premature codon in tumours, is an  indication that a conventional type II GnRH system is 
absent in humans [Cheng and Leung 2005, Pawson et al. 2005]. 
 
1.7 Evolution of the GnRH gene 
The origin of the GnRH molecule may precede the evolution of the vertebrates or even the 
invertebrates. GnRH is an example of a peptide whose gene has apparently undergone 
duplication to produce a second form of peptide. Duplicated genes may relocate to another 
portion of the genome [Sherwood et al. 1993]. 
 
The regulation of reproduction by GnRH has been highly conserved during 500 million years 
of vertebrate evolution despite the fact its amino acid sequence varies by 50%. The 
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constraints that appear to have limited the GnRH molecule to substitutions that are 
exclusively in positions 5, 7 and 8, may be related to receptor binding [Sherwood et al. 
1993]. In order to study the evolutionary relationship among GnRH forms, a molecular 
phylogenetic reconstruction technique (the phylogenetic tree) [White et al. 1998] was used to 
show the existence of three evolutionary distinct GnRH groups. These are “releasing” forms 
localized to the hypothalamus (GnRH I), forms previously localized solely to the midbrain 
nuclei (GnRH II), and forms localized to the telencephalon in several fish species (GnRH 
III). The structure of the tree suggests that multiple forms of GnRH exist in many different 
species because of their ancient duplications of a gene encoding GnRH. GnRH I and GnRH 
II include representatives from fish and mammals. The origin of GnRH III is less clear 
because there are only representatives from fish in this group [White et al. 1995].  
 
The type II GnRH seems to have been conserved longer than the mammalian GnRH type I. 
This peptide appears in all classes of vertebrates through primitive placental mammals, 
revealing that it has remained unchanged for decades, also indicating an important conserved 
role and a discriminating receptor (or receptors) that have been selected against any structural 
change in the ligand. This points to essential functions, that have yet to be identified [Millar 
et al. 2001, Millar et al. 2004].  
 
Recent studies provided evidence for the presence of a functional type II GnRH receptor in 
primates and pigs, and a type III receptor for fish and amphibians. Besides the wide tissue 
distribution of GnRH II, it is becoming evident that a conventional type II receptor system, 
 
 
 
 
 40
specific for GnRH II, does not exist in humans [Pawson et al. 2003, Cheng and Leung 2005, 
Pawson et al. 2005]. 
 
1.8 General primate spermatogenesis and GnRH 
Various factors are important regarding the maintenance of spermatogenesis, e.g. the role of 
sex steroids and other hormones during this process have been reported. Gonadotropin-
Releasing Hormone (GnRH) is well known for its function in the reproductive processes of 
mammalian and non-mammalian species. The treatment with high doses of GnRH and its 
analogues was predicted as a potential means for enhancing fertility. Moreover, a decrease in 
reproductive function has also been shown with long-term administration of pharmacological 
doses GnRH or its agonists [Hsueh and Jones 1983, Clayton 1989].  
 
Two types of GnRHs in primates [Lescheid et al. 1997] and the cloning of the type I and II 
receptors have been reported [Santra et al. 2000, Millar et al. 2001]. GnRH has an indirect 
function on spermatogenesis since LH and FSH are mainly involved in the maintenance of 
spermatogenesis and GnRH regulates the synthesis and secretion of these gonadotropins, 
which in turn regulate the hormonal and gametogenic functions of the gonads. It seems that 
GnRH II and the mammalian type II GnRH receptor specifically regulate FSH secretion, a 
peptide hormone involved in the development of meiotic spermatocytes and post meiotic 
spermatids [Conn et al. 1986, Glander and Krantzsch 1997]. In an in vivo study, a synthetic 
GnRH II was administered to the Rhesus macaque and the results confirmed that GnRH II is 
indeed the potent stimulator of gonodal release. A difference in the mechanism of the two 
peptides also became clear in the involvement of two different routes by which each peptide 
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could reach the pituitary to coordinate control of gonadosteroidogenesis and sperm 
production [Lescheid et al. 1997]. The results of an in vitro study, using monkey pituitary 
cultures, confirmed that GnRH II stimulates FSH and LH secretion, but that this action 
occurs via the GnRH I receptor and that the GnRH II receptor found in the primate brain may 
have a unique function other than regulation of gonadotropin secretion [Densmore and 
Urbanski 2003, Okada et al. 2003].  
 
The production of spermatozoa and the secretion of testosterone by the testis are both 
dependent on stimulation by the pituitary gonadotropins, follicle-stimulating hormone (FSH) 
and luteinising hormone (LH). Testosterone, which is essential for the initiation and 
maintenance of spermatogenesis, is secreted by the Sertoli, Leydig and peritubular cells. 
Sertoli cell number is an important determinant of the maximum achievable sperm output, 
but another key factor is the efficiency of spermatogenesis. Large differences between 
species were found when daily sperm productions were compared in terms of per gram of 
testis and spermatid versus Sertoli cell ratio. Of the nonhuman primates that have been 
investigated, the Rhesus monkey shows vastly superior efficiency of spermatogenesis 
compared to man, whereas the orang-utan and Cynomolgus monkey (Macaca fascicularis)  
are somewhat intermediate [Sharpe 1994]. The most notable differences between non-human 
primates and man are the number of generations of differentiated B spermatogonia (four in 
the monkey and one in man). Other differences include the duration of spermatogenesis, 
which in the monkey is 48 days, whereas that for man has been reported to vary around 74 
days [Plant and Marshall 2001]. The only resemblance in humans and Vervets (Chlorocebus 
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aethiops) is the multiple stages of spermatogenesis observed in a transverse section of a 
seminiferous tubule [van der Horst 2005]. 
 
The FSH receptor is expressed in the testes of the Cynomolgus monkey (Macaca 
fascicularis) and various studies of non-primate species have demonstrated that FSH binding 
in the testis is restricted to the Sertoli cells. Recently, a study provided compelling evidence 
for the view that gonadotropin control of testicular inhibin B secretion by the primate testis 
involves opposing stimulatory and inhibitory actions of FSH and LH, respectively. FSH is 
posited to act directly on the Sertoli cell and LH appears to be mediated by a paracrine action 
of testosterone from the Leydig cell to regulate inhibin-B gene expression by Sertoli cells 
[Ramaswamy et al. 2003].  
 
Many in vitro and in vivo systems have been used to study regulation of spermatogenesis by 
FSH and testosterone. FSH has a key role in the development of the immature testis, 
particularly by controlling Sertoli cell proliferation. To support this action of FSH, a study in 
foetal hypophysectomy in the Rhesus monkey resulted at term in a marked reduction in 
testicular size, suggesting that gonadotropin secretion by the foetal pituitary plays an 
important role in regulating Sertoli cell proliferation in utero.   
 
The role of FSH in the initiation and maintenance of testicular function in higher primates 
also confirmed marked species differences. Most notably, although hypophysectomy of adult 
primates leads to regression of the seminiferous epithelium, as it does in rats, only Sertoli 
cells and stem spermatogonia remain after removal of the pituitary. In the rat, these cells are 
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arrested during spermiogenesis [Plant and Marshall 2001]. Thus, in primates, the 
gonadotropic hormones are obligatory for development to differentiated spermatogonia, 
spermatocytes and spermatids; whereas in rats it appears that a limited number of spermatids 
may be produced in the absence of a gonadotropin drive [Plant and Marshall 2001]. 
 
Based on relatively selective withdrawal and replacement studies, it was shown that FSH is 
important in the progression of type A to B spermatogonia and, in synergy with testosterone, 
in regulating germ cell viability. Acute suppression models, such as hypophysectomy and 
GnRH antagonist treatment, have been used to demonstrate the role of FSH and testosterone 
in the maintenance of germ cell viability. Acute gonadotropin suppression resulted in germ 
cell death and exogenous testosterone suppressed both FSH and LH in primates (Macaque 
monkeys), profoundly impairing spermatogenesis. During this action, testosterone acts 
directly at both the hypothalamus and anterior pituitary. Even though FSH has an important 
role in spermatogenesis, the abolition of FSH secretion alone will not prevent either the 
initiation or maintenance of spermatogenesis and therefore will not lead to azoospermia 
[Plant and Marshall 2001, Anderson and Baird 2002, McLachlan et al. 2002]. 
 
Since primates share very similar hormonal dependencies and structural patterns of 
spermatogenesis compared to humans, methods for the development of safe and reversible 
male hormonal contraception are being investigated. Various studies have shown the effect 
of acute and chronic effect of GnRH antagonist treatment in male primates. Chronic 
antagonist treatment resulted in decrease in testicular volumes and ejaculate [Bint Akhtar et 
al. 1985] and the induction of azoospermia within nine weeks in male Cynomologus 
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monkeys (Macaca fascicularis)  [Weinbauer et al. 1987a, Weinbauer et al. 1987b]. In the 
male Bonnet monkey (Macaca radiata), no ejaculate could be obtained by week six of 
antagonist treatment [Rao et al. 1990]. 
 
Although azoospermia can be achieved by daily GnRH antagonist treatment, the continuous 
infusion of large doses of antagonist can cause undesirable side effects. A significant loss of 
body weight was reported for treated male Rhesus monkeys (Macaca mulatta) with a high 
dose, but  a low dose GnRH infusion by means of using osmotic mini pumps did not alter the 
bodyweight [Mann et al. 1987]. Similar results on body weights have been reported for the 
male Bonnet monkey on a low dose mini pump infusion. In all the studies reported, the 
inhibitory effects of GnRH antagonists were reversible and serum hormones, testis size and 
sperm counts returned to pre-treatment values.  
 
Seminal tubular fluid (STF) has always been viewed primarily as a means of transporting 
spermatozoa, inhibin and other substances out of the testis, but it was hypothesized as 
perhaps the single most important factor in the regulation and maintenance of 
spermatogenesis. It is the secretion of STF that changes first, in virtually every situation in 
which spermatogenesis modifies, whether during puberty, seasonal regression of the testis or 
in the failure of spermatogenesis after the withdrawal of testosterone. Nearly every 
messenger protein, nutrient and energy source has to be transported to the germ cells from 
the Sertoli cells, and STF is the major route via which this can occur. Since GnRH II is found 
in tissues such as in the baboon testis, epididymis and seminal vesicle [Siler-Khodr et al. 
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2003], STF and GnRH II regulation might play an important role in the maintenance of 
primate spermatogenesis. 
 
1.9   Spermatology of the Vervet monkey 
Most studies on Vervet semen were confined to investigating sperm concentrations and 
motility. The percentage motility reported for Vervet monkey sperm seems to be in the range 
of 34% to 58%. Semen samples from five non-human primate species were reported; a mean 
motility of 53% was described for three Vervet monkeys [Roussel and Austin 1967]. Another 
study involving Vervets, reported sperm motility ranging from 34% to 38% [Ackerman and 
Roussel 1968]. Other parameters such as sperm concentrations and ejaculate volumes were 
also investigated. Ejaculate volumes ranging from 0.9ml to 1.24ml and sperm concentration 
from 57 million/ml to 440 million/ml were reported [Valerio and Dalgard 1975, Hendrickx et 
al. 1978].  
 
Results of semen analysis were reported from a closed breeding colony of Vervet monkeys 
where breeding males were compared to singly caged males [Seier et al. 1989]. The average 
sperm motility for 11 breeding males and 58 singly caged males was 43% and 55%, 
respectively. A total semen volume of 0.45 – 0.86ml and a mean concentration per ml 
ranging from 117 to 185 (x106) was reported. The values obtained were much lower than 
described for Macaques, but were relatively the same as previous findings for Vervet 
monkeys. However, large variations in semen characteristics were found within individuals, 
such as sperm concentration and motility that differed by 100% and more in at least 2 
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consecutive ejaculates from 21 males. Considerable differences in a consecutive ejaculate 
from the same individual were also reported [Seier 1995]. 
 
Abnormalities of the sperm were also investigated. The most common morphological 
abnormality in the same colony of Vervet monkeys (as above), were detached tails. Other 
abnormalities were microcephalus, macrocephalus, narrow tapered heads, cytoplasmic 
droplets, thick midpieces and bent or coiled tails [Seier et al. 1989]. The same author later 
reported that tail abnormalities predominate in the sperm of Vervet monkeys and that males 
with the highest number of folded or coiled tails were successful breeders [Seier 1995]. A 
total of 28 different sperm abnormalities were found amongst the ejaculates of 28 Vervet 
monkeys. From a total of 13 head abnormalities, three types were found in colony-bred 
individuals. In a total of seven midpiece abnormalities, only three types were found in wild- 
caught individuals, while end piece abnormalities occurred in both groups. 
 
Fertility potential of cryopreserved semen can be poor due to damage to the acrosome and 
the Vervet is a good model for studies on cryopreservation. The effects on post-thawed 
sperm and acrosomal status of the Vervet monkey have been reported. A mean recovery of 
63.6% and progressive motility of 43% for Vervet monkey sperm was found with a well-
established cryopreservation method. Acrosome damage was found to be higher for post-
thawed sperm compared to damage before cryopreservation. Intact acrosome levels were 
61.2% at pre-freeze versus 31.6% at post-thaw and for severely damaged acrosome 
(equatorial staining) 16.8% compared to 29% for pre-freeze and post-thawed sperm. 
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Acrosome losses were found to be higher for cryopreserved sperm [Conradie et al. 1994, 
Seier 1995].  
 
The maturation of Vervet sperm motility was also explored using sperm kinematics. A 
computer-aided sperm motility analysis system revealed clear trends in the development of 
sperm motility in the epididymis and vas deferens. The motion of spermatozoa from the 
caput epididymis was sluggish and irregular but the motility increased sharply as it moved 
through the corpus epididymis and continued to improve through the cauda epididymis and 
vas deferens. The results proved that the full maturation of motion capabilities was only 
completed once spermatozoa reached the vas deferens with final emergence in the ejaculate 
[van der Horst et al. 1999].  
 
1.10 Purpose of the study 
Gonadotropin-Releasing Hormone (GnRH) and its receptors have been cloned and its 
structure and functions have been studied extensively in both mammalian and non-
mammalian vertebrates. GnRH I and GnRH II are found in humans and primates along with 
a functional type II receptor that has been located in primates but seems to be non-functional 
in humans. 
 
In addition to the established paracrine role, it is possible that this peptide has autocrine 
functions in several reproductive and non-reproductive tissues. In male reproduction, these 
peptides play an important role in the maintenance of spermatogenesis, sperm maturation and 
fertilization. In vitro expression and immunoidentification of a GnRH receptor in mouse and 
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rat testicular germ cells and in the acrosomal region of human sperm have been reported.  A 
GnRH II receptor transcript has also been located in human sperm, but it contains a stop 
codon, and the function is unknown. In addition, GnRH-like substances have been located in 
human and primate testis, epididymis and seminal fluid with receptors that seem to be 
situated in the Leydig cells.  
 
In vitro studies on human sperm have confirmed that GnRH plays a role in sperm binding 
during fertilization and that GnRH and its antagonists did not affect the motility or 
percentage of acrosome-reacted spermatozoa. These findings raise a challenging question as 
to how GnRH will affect primate sperm. Primates do have a functional type II receptor and 
the fact that GnRH II is found ubiquitously in primate reproductive tissue suggests that this 
peptide has a biological function in sperm. Further, the type II receptor has been confirmed to 
specifically regulate FSH secretion in primates. However, the investigation of the function of 
GnRH and its receptors in primate male reproduction has been mainly limited to either sex 
hormone control studies or understanding the mechanism of the contraceptive activity of 
GnRH. A literature search provided no evidence of any in vitro or in vivo work on the direct 
effect of GnRH on primate sperm. The possible role of GnRH in regulating sperm motility 
and on acrosome reaction, possibly via one or both GnRH receptors, needs consideration in 
the above context. 
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Specific aims are: 
1. To investigate the effect of GnRH I and GnRH II at different concentrations on 
sperm acrosome status.  
2. To study the effect of GnRH I and GnRH II at different concentrations on the 
motility of the Vervet monkey sperm by computer aided sperm analysis. 
 
The results should improve our understanding of the function of both gonadotrophin 
releasing hormones and their direct effect on Vervet monkey spermatozoa in vitro. 
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CHAPTER 2 
Materials and Methods 
2. The non-human primate model – Vervet monkey 
The Vervet monkey (Chlorocebus aethiops), also called the African green monkey, is one of 
four primate species indigenous to Southern Africa. They adapt well to captivity and breed 
successfully within a closed environment. It is widely accepted that defined captive-bred 
primates are preferable to wild-caught individuals as an ideal model for biomedical research 
[Seier 1986].  
 
2.1 The choice of subjects for this study 
Adult males were chosen randomly but availability at the time of sampling determined, and 
often limited, the choice. The criteria for inclusion were sexual maturity and a 50% 
progressive motility rate for spermatozoa, due to the rapid decline in semen motility. Ten 
males who consistently offered reliable sperm concentrations, motility and normal 
morphology, were retained for this study. 
 
All animals were from a captive-bred stock of Vervet monkeys with a history of successful 
reproductive performance for two generations. All males used were successful breeders and 
were housed singly for the duration of the study. The conditions in the closed indoor 
environment were maintained at 25 - 27°C, a humidity of 45%, about 15-air changes/hour 
and a photoperiod of 12 hours [Seier 1986]. All individuals had regular access to exercise 
cages and environmental enrichment (foraging and food puzzles).  
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2.2 Spermatology and medium 
2.2.1 Semen collection 
Semen was obtained by peri-prostatic electro stimulation applied per rectum. The electro 
ejaculator consisted of a 175mm long homemade rectal probe with a diameter of 15.4mm and 
two brass bands embedded in the tip. Both bands were wired internally to contacts at the base 
of the probe. The two probe contacts were connected to a transformer with five taps, which 
controlled voltage output from 2.5 – 5.5V by 1.0V increments and had one additional 8.0V 
output [Seier et al. 1989, Cseh et al. 2000] (Fig. 2.1). 
 
To achieve ejaculation, a male was placed in dorsal recumbency after anaesthesia with 
ketamine hydrochloride (Anaket V, Cape Medical Supplies, Cape Town), at 10mg/kg 
bodyweight intramuscularly. The probe was lubricated with a gel containing disinfectant 
(Betadine, Lakato Vet., Cape Town) and inserted into the rectum with the brass bands at the 
level of the prostate gland.  
 
Electro stimulation was started at 2.5V and the full current was applied by switching on the 
transformer. The probe was held steady at a point until erection was achieved. The current 
was applied for 1-2 minutes followed by a 15-20 second rest period. Voltages were increased 
by connecting the leads of the probe into the tap of the transformer for the next higher 
voltage, until ejaculation was achieved. All ejaculates were collected in a 10ml pre- warmed 
graduated glass tube. A total of 84 ejaculates were collected for this study. 
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Figure 2.1   Electro ejaculation equipment 
 
2.2.2 Extenders for semen 
Because sperm motility of the Vervet monkey declines rapidly if spermatozoa are maintained 
in seminal fluid [Seier et al. 1989], semen was diluted with Hams F10 extender. A volume of 
25ml Hams F10 was used containing 0.247g Hams F10 nutrient mixture, 0.03g NaHCO3 
(Sodium Bicarbonate) (Sigma, Cape Town), 0.025g Bovine Serum Albumin and 25ml 
distilled water. The pH was adjusted to 7.5 with Na2HPO4 (dibasic) or NaH2PO4 (monobasic) 
(Sigma, Cape Town) and a 744 Metrohm pH Meter (Metrohm Ltd., Switzerland). The 
extender was freshly prepared for every experiment one hour prior to semen collection. The 
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medium was kept in a water bath at 37°C throughout the course of the experiment and 
discarded at the end. 
 
2.2.3   Medium for acrosome staining 
Fluorescein isothiocyanate-conjugated peanut agglutinin (FITC-PNA) was used for acrosome 
staining. A stock solution was prepared by dissolving 5mg of FITC-PNA in 5ml phosphate-
buffered saline (PBS), and it was stored in 600µl aliquots at -20°C. For the final working 
solution, 15.5ml PBS were added to a 600µl aliquot of FITC-PNA.  
All buffers and chemicals were purchased from Sigma Chemicals (Cape Town, South 
Africa). 
 
2.2.4 GnRH analogues 
The 2 peptides with a molecular weight of 1411 for GnRH I and 1463 for GnRH II were 
prepared as a stock solution of 50µl aliquots at a concentration of 10-3M, with 20% propylene 
glycol as the vehicle medium. Analogues were stored in 1ml cryotubes at -20°C. Analogues 
and propylene glycol were supplied by Prof. A Katz from the Receptor Biology Research 
Group, UCT Medical School, Cape Town, South Africa. 
 
2.3    In vitro incubation 
2.3.1 Swim-up incubation 
Due to the coagulation of semen, the standard swim-up [Vijayakumar et al. 1987, Oliva et al. 
1991 and Esteves et al. 2000] had to be adjusted according to the sample to get the most 
motile sperm. In samples with fluid semen, a volume of 0.5ml seminal plasma was slowly 
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expelled at the bottom of a 5ml plastic tube containing pre-warmed (37°C) 1ml Hams F10. If 
the ejaculate contained only coagulum, 1ml of the extender was layered over the sample to 
allow spermatozoa to swim out of the coagulant mass. The tubes were placed at a 45° angle 
and incubated for 10 minutes in a water bath at 35°C. During this period, motile spermatozoa 
migrated from the under layered sperm suspension to the upper layer. 
 
After 10 minutes, a drop of the swim-up was collected with a glass Pasteur pipette from the 
upper layer of the extender and observed under a microscope at 100 and 400x 
magnifications. If the swim-up was estimated to yield 50% motile sperm, the top 550µl of the 
supernatant was gently aspirated with a Gilson pipette and the specimen was divided into 
three equal aliquots of 180µl. The first aliquot received no treatment (control) and 20µl 
Hams F10 extender was added with a positive displacement pipette. The second and the third 
aliquot sperm samples were treated by adding 20µl of GnRH I and 20µl of GnRH II, 
respectively. All three aliquots were kept in loosely capped 1ml cryotubes (LASEC, Cape 
Town) and placed in a water bath at 37°C. The effect of concentrations 10-5M, 10-6M and 10-
8M for GnRH I and II on motile sperm was evaluated for one hour. The time factor only 
allowed one peptide and one concentration to be evaluated at a time. The effect of the GnRH 
vehicle medium, propylene glycol (0.2%), was analyzed separately in the same manner as for 
the GnRH exposure tests (refer to table 2.2). 
 
To prevent “cold shock” to motile sperm [Faulkner 1971], all tubes, pipette tips, extender and 
microscope slides used during each experiment, were pre-warmed in either the water bath 
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(Forma Scientific, Scientific Associates, Tokai, Cape Town) or with temperature controlled 
heated stages (Photax, Protea Holdings Cape, Cape Town) and kept at 37°C.  
 
2.3.2  Staining for acrosomal integrity 
For the analysis of motile sperm acrosomal integrity [Mortimer et al. 1990], two slides were 
stained for every time point (refer to table 2.2) for control, GnRH treatment and propylene 
glycol. A 20µl drop of each sperm specimen was removed and spread over one end of a 
microscope slide and left to air-dry in the dark. Air dried slides were fixed for five minutes 
by immersion in 95% ethanol, followed by more air-drying. Slides were stained at room 
temperature for 15-20 minutes in a foil covered Coplin jar containing 100µg/ml FITC/PNA 
solution. The slides were washed by gently dipping (x3) in PBS and fixed by immersion in 
4% para-formaldehyde fixative for 15 minutes. After rinsing gently with PBS, the slides were 
allowed to air dry, which was followed by mounting with non-fluorescing media containing 
anti-fading n-Propyl Gallate (Sigma, Cape Town) and 22 x 22 cover slips. Scoring was 
completed within 24 hours of staining.   
 
2.3.3 Evaluation for acrosomal integrity 
Slides were examined with an Olympus (BX 50) microscope (Wirsam Scientific, Cape 
Town, South Africa) with a 100-x objective (Uplan FI Oil Ph3) and appropriate filters 
(Olympus U-MWB with BP 450-480) for the FITC-PNA labels. The proportions of 
spermatozoa with fluorescent patterns were recorded for labels I= intact acrosome, 
III= equatorial staining and IV= no acrosome (Fig. 2.2). Type II pattern was not observed in 
this study. The results were expressed as percentages of 200 counted spermatozoa. 
 
 
 
 
 56
 
Figure 2.2  PNA labelling patterns of Vervet monkey spermatozoa 
FITC-PNA lectin (According to Mortimer et al. 1990).  
Fluorescence pattern I showing intensely fluorescent region of acrosome intact sperm and the dark 
postacrosomal region. Fluorescence pattern II displaying irregular fluorescence of the acrosomal region. Note 
this type of fluorescence is also limited to the acrosomal region of the head. Fluorescence pattern III showing 
bright fluorescence at the equatorial region of the sperm. Note the lack of fluorescence at both the acrosomal 
and post-acrosomal regions. Fluorescence pattern IV, showing lack of fluorescence on the sperm head due to 
absence of the acrosome. 
 
2.4 Motility 
2.4.1 Subjective motility 
Immediately after ejaculation, a drop of semen was placed under a cover slip on a pre-
warmed (37°C) microscope slide, and motility and speed of forward progression (FP) were 
evaluated under a microscope with bright field illumination at 100 and 400x magnifications. 
Motility was estimated in 10% units of progressively motile spermatozoa and the FP rated on 
a scale of 0 – 4 [Seier et al. 1989]. Zero represented no progressive motility and four 
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maximum speed. Only samples with more than 50% progressive motility were used for the 
experimental protocols. 
 
2.4.2 Computer Aided Sperm Motility Analysis (CASMA) 
A 10µl drop of the sample was pipetted onto a microscope slide and subsequently mounted 
with a cover slip, then placed on the pre-warmed (37°C) stage of an Olympus CH2 
microscope. Electrical coils built into the microscope stage ensured that the temperature was 
accurately controlled within 0.1oC by means of an external temperature control device 
developed by Wirsam Scientific (Cape Town, South Africa) for the Olympus CH2 (see 
Fig.2.3).   
 
Sperm motion characteristics of the three samples of each experiment including control, 
GnRH I and GnRH II, were recorded at 0 minutes, 15 minutes, 30 minutes and 60 minutes. 
After the GnRH treatment, 2 – 5 minutes were allowed before analyzing the sample. 
Sperm motility for each treatment and each experiment was recorded onto a video tape using 
a Phillips VHS recorder connected to a Panasonic monitor. Sperm motility was evaluated by 
the computer-aided sperm motility analysis (CASMA) system, Sperm Motility Quantifier 
(version 1.01: Wirsam Scientific & Precision Equipment (Pty) Ltd, South Africa),   (Fig.2.3).  
 
The recordings of sperm motion were captured at an analysis rate of 50 Hz. The minimum 
and maximum sperm size was preset at 6 and 47 pixels and spermatozoa were tracked for 0.7 
seconds [Mdhluli and van der Horst 2002]. Ten fields from each slide were recorded with a 
maximum of a 100 - 200 motile spermatozoa. Randomly representative sperm trajectories 
 
 
 
 
 58
were saved as *.tiff files to facilitate qualitative comparison of patterns of sperm motility for 
each time point of GnRH treatment and the controls. Seven sperm motion characteristics, viz. 
curvilinear velocity (VCL), straight-line velocity (VSL), average path velocity (VAP), 
amplitude of lateral head displacement (ALH), linearity (LIN), mean angular displacement 
(MAD) and  percent motility, were measured [van der Horst et al. 1999]  (Table 2.1).  
 
 
 
Figure 2.3  Sperm Motility Quantifier system and equipment for recording sperm                         
motility 
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Table 2.1  Sperm motility quantification variables  
 
Variable Definition Abbreviations Units 
Straight line velocity   
 
Time-averaged velocity of sperm 
head projected along straight line 
between its first & last detected 
positions 
VSL 
 
µm/s 
 
Curvilinear velocity 
 
Time-averaged velocity of sperm 
head along its actual path  
VCL 
 
µm/s
Average path  velocity    Time-averaged velocity of sperm  
head projecting along its spatial  
average trajectory            
              
VAP µm/s 
 
Linearity Ratio of projected length to total 
length of curvilinear trajectory; 
LIN = VSL/VCL     
LIN % 
 
Mean Angular 
Displacement 
Measured in Radian = 
Radius/3.14  x 180 
 
MAD Radians 
Amplitude of lateral 
head displacement 
 
Magnitude of lateral 
displacement of a sperm head 
about its average path. 
 
ALH µm 
Total motility         Percentage motility of 
spermatozoa swimming with a 
VCL>20µm.sec and 
VSL>9µm.sec, the rest were 
considered  immotile 
- % 
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Table 2.2   Experimental layout for acrosome status and sperm motility evaluations for             
        GnRH I & II at different concentrations for one hour from a total of 84             
        ejaculates. 
 
TIME POINTS (minutes) 
 0 Minutes        n 15 Minutes      n 30 Minutes      n 60 Minutes      n 
GnRH I 
Control 
 
10-5M 
 
 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       6 
 
SMQ                 6 
FITC-PNA        - 
SMQ                 6 
FITC                 - 
 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       6 
 
SMQ                  6 
FITC-PNA         6 
SMQ                  6 
FITC-PNA         6 
 
Control 
 
10-6M 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       - 
SMQ                6 
FITC-PNA       - 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       6 
SMQ                  6 
FITC-PNA         6 
SMQ                  6 
FITC-PNA         6 
 
Control 
10-8M 
 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       - 
SMQ                6 
FITC-PNA        - 
SMQ                6 
FITC-PNA       6 
SMQ                 6 
FITC-PNA        6 
SMQ                  6 
FITC-PNA         6 
SMQ                   6 
FITC-PNA          6 
 
GnRH II 
Control 
 
10-5M 
 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       6 
 
SMQ                6 
FITC-PNA       - 
SMQ                6 
FITC-PNA       - 
 
SMQ                   6 
FITC-PNA          6 
SMQ                   6 
FITC-PNA          6 
 
SMQ                   6 
FITC-PNA          6 
SMQ                   6 
FITC-PNA          6 
 
Control 
10-6M 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       6 
SMQ                6 
FITC-PNA       - 
SMQ                6 
FITC-PNA       - 
SMQ                  6 
FITC-PNA         6 
SMQ                   6 
FITC-PNA          6 
SMQ                   6 
FITC-PNA          6 
SMQ                    6 
FITC-PNA           6 
Control 
10-8M 
SMQ               6 
FITC-PNA      6 
SMQ               6 
FITC-PNA      6 
SMQ                6 
FITC-PNA       - 
SMQ                6 
FITC-PNA       -
SMQ                   6 
FITC-PNA          6 
SMQ                   6 
FITC-PNA          6 
SMQ                    6 
FITC-PNA           6 
SMQ                    6 
FITC-PNA           6 
Peptide   
vehicle 
Control 
 
Propylene      
glycol 0.2% 
 
 
 
SMQ              6 
FITC-PNA     6 
SMQ              6 
FITC-PNA     6 
 
 
SMQ                6 
FITC-PNA        - 
SMQ                6 
FITC-PNA        - 
 
 
SMQ                  6 
FITC-PNA         6 
SMQ                  6 
FITC-PNA         6 
 
 
SMQ                    6 
FITC-PNA           6 
SMQ                    6 
FITC                    6 
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2.5 Statistical analysis 
Descriptive statistics were used to analyze data and ANOVA was used to compare more than 
two sets of data at a given time interval.  Student-Newman-Keuls tests for all pair wise 
comparisons were subsequently performed. In instances where data did not have a normal 
distribution, Kruskal-Wallis analysis combined with unpaired Wilcoxon analysis were 
applied. In all instances the statistical package, MedCalc for Windows, version 4.16 
(MedCalc Software, Mariakerke, Belgium), was used.  
 
Graphic presentations of data were done using Excel spreadsheets and concomitant 
histogram presentations. 
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CHAPTER 3 
Results 
3 Electro ejaculation 
The method of electro ejaculation consistently produced ejaculates from all male Vervet 
monkeys. During electro stimulation, the Vervets responded with strong contractions of the 
thigh muscles, testicular and tail movements, erection with enlargement of the glans penis 
and ejaculation. Weakening of these responses and cessation of erection indicated the need to 
change to the next higher current. There were inter-individual differences in the stimulation 
period required to achieve ejaculation and some males occasionally ejaculated before 
erection or during rest periods. Urination frequently occurred if the males were stimulated 
after ejaculation and at 5.5 – 8.0V of electro stimulation. 
 
3.1 Hams F10 extender 
In this study, Hams F10 that consisted of all amino acids, fatty acids and mineral salts, as 
well as protein (BSA), was used as the physiological extender in all experiments and 
consistently supported sperm motility for the duration of the experiment.  
 
3.2 Swim-up incubation  
The swim-up method provided sufficient motile sperm, even though the method had to be 
adjusted from time to time to accommodate coagulated ejaculates. Injecting semen at the 
bottom of the extender or layering Hams F10 on top of the coagulum continuously resulted in 
a sample containing a high quality of motile sperm, clear of dead sperm and cellular debris.  
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3.3 Acrosomal integrity  
There were three distinct staining patterns of FITC-PNA in the acrosomal and equatorial 
regions of the Vervet monkey spermatozoa.  
 
 
            
        Pattern I     Pattern III          Pattern IV                                         
    Intact Acrosome           Equatorial band    Absent acrosome  
 
Figure 3.1 Staining of Vervet monkey spermatozoa after labelling with FITC-PNA 
The bar at the bottom of pattern I photomicrograph represents 6.3μm (From Mdhluli 2003). 
 
 
3.3.1 Intact acrosome (Pattern I) 
There were no statistically significant differences in intact acrosomes (Figure 3.1) of the 
treated groups (GnRH I & II at concentrations of 10-5M, 10-6M and 10-8M) compared to the 
control. There were also no statistically significant differences between the vehicle 
(propylene glycol 0.2%), the control or any treatment groups. The means and standard 
deviations for all groups at the three different time points are summarized in Table 3.1, as 
well as graphically represented in Figures 3.2 to 3.4. 
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Table 3.1   Percentage (means ± SD) of intact acrosomes for GnRH I & II  
                   (concentrations 10-5 M, 10-6M, 10-8M), propylene glycol 0.2% and controls. 
 
Treatment 0 min 30 min 60 min 
Propylene glycol 0.2% control 94.42 ± 7.61 91.75 ± 11.72 92.08 ± 6.05 
Propylene glycol 0.2% 93.42 ± 6.05 94.75 ± 2.70 95.02 ± 4.65 
GnRH control  97.11 ± 4.80 95.78 ± 4.87 96.61 ± 5.42 
GnRH I 10-5M 97.30 ± 2.54 98.00 ± 0.97 98.30 ± 1.83 
GnRH I 10-6M 96.40 ± 5.83 96.30 ± 7.05 96.30 ± 4.55 
GnRH I 10-8M 90.10 ± 7.47 90.60 ± 7.80 92.30 ± 8.10 
GnRH II 10-5M 97.60 ± 2.96 96.70 ± 1.44 96.40 ± 3.20 
GnRH II 10-6M 95.40 ± 6.41 97.30 ± 5.36 96.00 ± 6.62 
GnRH II 10-8M 92.30 ± 5.26 93.10 ± 5.58 94.50 ± 3.87 
 
 
3.3.2 Equatorial band (Pattern III) 
The percentage of equatorial band staining (Figure 3.1) showed a larger variation within 
groups than between groups when the control was compared to all treatment groups for all 
time intervals. The large variation in each group is also exemplified as relatively large 
standard deviations (Table 3.2).  
 
Consequently, no statistically significant differences were found between the control and 
GnRH I & II at concentrations of 10-5M to 10-8M as well as the vehicle, propylene glycol 
(Figure 3.5 to 3.7). The means and standard deviations for all groups at three different time 
points are summarized in Table 3.2.   
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Table 3.2  Percentage (means ± SD) of equatorial band staining for GnRH I & II       
      (concentrations 10-5M, 10-6M, 10-8M), propylene glycol 0.2%, and controls. 
 
Treatment 0 min 30 min 60 min 
Propylene glycol 0.2% control 1.80 ± 2.90 4.30 ± 6.50 4.30 ± 4.40 
Propylene glycol 0.2% 3.40 ± 1.90 2.50 ± 1.00 3.50 ± 2.20 
GnRH control 1.31 ± 3.37 1.89 ± 2.76 1.56 ± 3.43 
GnRH I 10-5M  0.58 ± 0.80 0.83 ± 0.68 0.50 ± 0.58 
GnRH I 10-6M 0.20 ± 0.41 0.40 ± 0.66 1.70 ± 1.51 
GnRH I 10-8M 4.60 ± 7.18 5.30 ± 5.18 2.60 ± 7.01 
GnRH II 10-5M 0.41 ± 0.66 0.58 ± 0.80 0.83 ± 0.99 
GnRH II 10-6M 0.70 ± 1.40 1.70 ± 1.97 1.70 ± 1.74 
GnRH II 10-8M 3.60 ± 4.31 3.40 ± 3.34 3.40 ± 4.02 
 
 
3.3.3 Absent acrosome (Pattern IV) 
The results for all groups showing the percentage of absent acrosomes (Figure 3.1) at three 
different time points are summarized in Table 3.3 and shown in Figures 3.8 to 3.10. The 
results clearly show that a small percentage of acrosomes are absent in all groups. 
Furthermore, no statistically significant differences were evident between the controls and 
any of the experimental groups.  The results for absent acrosomes in controls and treatment 
groups accordingly follow the same trend as for the previous two staining patterns (bright 
and equatorial).  
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Table 3.3   Percentage (means ± SD) of absent acrosomes for GnRH I & II 
                   concentrations (10-5M, 10-6M, 10-8M), propylene glycol 0.2% and controls. 
 
Treatment 0 min 30 min 60 min 
Propylene glycol 0.2% control    3.80 ± 4.80    3.70 ± 5.50 2.20 ± 1.90 
Propylene glycol 0.2% 3.20 ± 4.20 2.20 ± 2.50 1.80 ± 2.40 
GnRH control 1.58 ± 3.22 2.22 ± 3.47 2.19 ± 4.85 
GnRH I 10-5M 2.08 ± 2.35 1.33 ± 0.82 1.00 ± 0.71 
GnRH I 10-6M 3.20 ± 5.91 3.30 ± 6.77 1.90 ± 3.50 
GnRH I 10-8M 5.20 ± 4.97 4.10 ± 2.96 2.40 ± 1.83 
GnRH II 10-5M 1.91 ± 2.89 1.33 ± 1.47 2.58 ± 3.54 
GnRH II 10-6M 3.10 ± 5.32 2.90 ± 6.90 2.30 ± 4.92 
GnRH II 10-8M 4.30 ± 3.61 3.50 ± 2.95 2.30 ± 1.70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
020
40
60
80
100
Control Prop. Glycol 0.2% GnRH I GnRH II
P
e
r
c
e
n
t
 
(
%
)
0 min 30 min 60 min
Figure 3.2
FITC-PNA staining for intact acr some with GnRH I & II treatment
at concentration 10-5M for one hour
T-bars represent +SD
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FITC-PNA staining for intact acrosome with GnRH I & II treatment
at concentration 10-6M for one hour
T-bars represent +SD
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Figure 3.4
FITC-PNA staining for intact acrosome with GnRH I & II treatment
at concentration 10-8M for one hour
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Figure 3.5
FITC-PNA staining for equatorial band with GnRH I & II treatment
at concentration 10-5M for one hour
T-bars represent +SD
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Figure 3.7
FITC-PNA staining for equatorial band with GnRH I & II treatment at 
the concentration 10-8M for one hour  
T-bars represent +SD
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Figure 3.8
FITC-PNA staining for absent acrosome with GnRH I & II treatment
at concentration 10-5M for one hour
T-bars represent +SD
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Figure 3.9
FITC-PNA staining for absent acrosome with GnRH I & II 
treatment at concentration 10-6M for one hour
T-bars represent +SD
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Figure 3.10
FITC-PNA staining for absent acrosome with GnRH I & II treatment at 
concentration 10-8M for one hour
T-bars represent +SD
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3.4 Sperm motility 
3.4.1 Computer Aided Sperm Motility Analysis (CASMA)  
There were noticeable changes in CASMA variables in the treated groups compared to the 
control and vehicle groups over a period of one hour. The most significant differences 
appeared to be a steady decline from 0 minutes to 60 minutes in all variables for samples 
treated with GnRH I & II at the concentration 10-8M. Table 3.4 demonstrates the quantitative 
(± SD) sperm motility results. 
 
 
 
3.4.2 Effect on CASMA parameters observed during one hour 
GnRH treatment was associated with statistically significant changes on CASMA parameters 
at different time points and different concentrations of GnRH I & II (for P- values see Table 
3.5) and subsequently described under 3.4.2.1 to 3.4.2.4. 
 
 
 
3.4.2.1  Immediate effect (0 - 5 minutes) 
A statistically significant decline (p< 0.05) in VCL (Figure 3.11), VSL (Figure 3.12), LIN 
(Figure 3.13) and VAP (Figure 3.14) was evident in groups treated with GnRH I & II at  
10-8M when compared to the control and Propylene Glycol (vehicle) group. There was a 
statistically significant increase in MAD (Figure 3.46) (p<0.05) for GnRH II at 10-8M when 
compared to the control.  However, no statistically significant differences were observed for 
ALH in the control versus treated groups (Figure 3.15). There were no significant differences 
between the GnRH control and the Propylene Glycol (PG) control for any parameter, which 
indicates no PG effect.   
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3.4.2.2 Effect at 15 minutes 
There were further statistically significant decreases in VCL, VSL, and LIN, at 15 minutes 
when GnRH I and II at 10-8M were compared to the control (Tables 3.4 and 3.5). In addition 
to the immediate affect there was a decline in VAP and ALH for both GnRH peptides at  
10-8M at 15 minutes, which was statistically significant when compared to the control 
(p<0.05) (Figures 3.11 – 3.15). MAD was still significantly enhanced for GnRH II at 10-8M 
when compared to the control (Figure 3.16). 
 
 
3.4.2.3  Effect at 30 minutes 
In comparison to the control and all other treated groups, groups GnRH I & II at 10-8M 
continued to show a significant decline in VCL, VSL, LIN, VAP, and ALH and an increase 
in MAD (Figure 3.11 – Figure 3.16). 
 
 
3.4.2.4  Effect at 60 minutes 
A statistically significant decline in groups treated with GnRH I & II at 10-8M compared to 
the control, was evident for VCL, VSL, LIN, VAP and ALH (Figure 3.11 – Figure 3.15). 
Furthermore, MAD continued to increase statistically significantly at a concentration of 
GnRH II 10-8M compared to the control (Figure 3.16). 
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Table 3.4 Means and standard deviations (means ± SD) for Computer Aided Sperm 
             Motility Analysis (CASMA) results 
 
Treatment Parameter 0 min 15 min 30 min 60 min 
GnRH control VCL 
VSL 
LIN 
ALH 
VAP 
MAD 
212.52 ± 54.77 
150.22 ± 39.97 
66.41 ±  9.75 
6.22 ±  2.59 
166.45 ± 38.78 
1.69 ± 0.38 
202.15 ± 53.04 
136.63 ± 37.20 
62.86 ± 8.33 
6.38 ± 2.29 
152.89 ± 38.28 
1.86 ± 0.36 
197.26 ± 66.91 
120.29 ± 54.45 
55.67 ± 14.66 
6.74 ± 2.92 
139.33 ± 54.00 
2.07 ± 0.52 
175.80 ± 51.73 
107.44 ± 34.75 
56.35 ± 9.96 
6.11 ± 2.29 
123.69 ± 36.80 
2.02 ± 0.40 
 
Propylene glycol 0.2% VCL 
VSL 
LIN 
ALH 
VAP 
MAD 
 
241.42 ± 42.26 
161.31 ± 41.35 
61.16 ± 12.33 
7.55 ± 1.96 
181.54 ± 34.00 
1.9 ± 0.36 
218.28 ± 32.34 
142.61 ± 44.92 
59.38 ± 14.10 
6.85 ± 1.04 
163.31 ± 39.77 
2.03 ± 0.46 
174.71 ± 22.22 
107.27 ± 34.66 
52.03 ± 12.19 
5.58 ± 0.71 
128.25 ± 29.03 
2.27 ± 0.35 
151.40 ± 59.66 
75.81 ± 41.70 
43.99 ± 11.34 
5.78 ± 2.74 
98.05 ± 40.12 
2.57 ± 0.39 
 
GnRH I 10-5M VCL 
VSL 
LIN 
ALH 
VAP 
MAD 
196.63 ± 30.27 
142.09 ± 21.98 
69.54 ± 8.12 
6.38 ± 1.93 
153.69 ± 20.64 
1.65 ± 0.34 
193.76 ± 46.60 
119.73 ± 27.97 
58.74 ± 4.02 
7.17 ± 2.40 
136.49 ± 32.40 
1.83 ± 0.30 
171.94 ± 49.98 
111.57 ± 48.30 
60.31 ± 18.22 
5.52 ± 2.61 
127.76 ± 45.01 
1.91 ± 0.60 
126.62 ± 48.14 
76.67 ± 53.42 
50.93 ± 20.91 
4.35 ± 1.02 
90.84 ± 49.97 
2.04 ± 0.51 
 
GnRH I 10-6M VCL 
VSL 
LIN 
ALH 
VAP 
MAD 
199.39 ± 66.74 
135.90 ± 48.38 
63.34 ± 12.93 
6.46 ± 3.22 
150.04 ± 51.54 
1.89 ± 0.58 
201.42 ± 59.85 
111.48 ± 37.48 
47.39 ± 8.71 
6.93 ± 2.68 
137.51 ± 37.20 
2.30 ± 0.35 
186.65 ± 90.85 
104.83 ± 51.30 
49.49 ± 12.70 
5.99 ± 4.36 
126.82 ± 48.40 
2.39 ± 0.42 
160.20 ± 42.47 
91.84 ± 32.35 
52.07 ± 10.79 
6.14 ± 2.38 
106.72 ± 33.88  
2.27 ± 0.40 
 
GnRH I 10-8M VCL 
VSL 
LIN 
ALH 
VAP 
MAD 
157.04 ± 37.85 
103.29 ± 25.21 
56.45 ± 12.77 
5.52 ± 1.48 
118.78 ± 27.51 
1.84 ± 0.47 
124.08 ± 14.05 
73.56 ± 14.87 
47.17 ± 8.08 
3.97 ± 0.84 
90.24 ± 14.16 
2.15 ± 0.43 
114.64 ± 28.05 
61.96 ± 36.81 
42.05 ± 17.54 
3.80 ± 1.30 
83.12 ± 27.60 
2.30 ± 0.58 
101.35 ± 27.05 
51.36 ± 27.66 
39.83 ± 11.93 
4.32 ± 0.78 
65.91 ± 25.26 
2.11 ± 0.53 
 
GnRH II 10-5M VCL 
VSL 
LIN 
ALH 
VAP 
MAD 
179.48 ± 28.43 
130.96 ± 20.22 
68.32 ± 7.07 
5.82 ± 1.58 
143.29 ± 21.55 
1.59 ±0.24 
178.73 ± 34.70 
108.03 ± 32.44 
54.73 ± 11.62 
6.71 ± 1.98 
125.97 ± 30.28 
2.07 ± 0.57 
176.20 ± 41.87 
102.14 ± 29.07 
54.35 ± 13.44 
6.64 ± 2.79 
120.25 ± 25.99 
2.16 ± 0.57 
151.81 ± 56.19 
91.49 ± 51.22 
54.34 ± 16.00 
5.66 ± 2.79 
108.73 ± 49.05 
2.05 ± 0.60 
 
GnRH II 10-6M VCL 
VSL 
LIN 
ALH 
VAP 
MAD 
191.73 ± 54.75  
122.95 ± 32.71 
58.85 ± 8.79 
6.11 ± 2.83 
126.98 ± 56.67 
2.12 ± 0.36 
162.27 ± 61.76 
93.75 ± 53.96 
47.87 ± 14.77 
4.72 ± 1.97 
119.66 ± 48.04 
2.41 ± 0.56 
 
167.55 ± 54.41 
100.67 ± 45.89 
50.71 ± 13.51 
4.77 ± 2.18 
123.78 ± 39.69 
2.29 ± 0.45 
172.82 ± 74.50 
90.96 ± 36.87 
48.68 ± 8.64 
6.65 ± 3.94 
113.81 ± 42.67 
2.40 ± 0.29 
 
GnRH II 10-8M VCL 
VSL 
LIN 
ALH 
VAP 
MAD 
137.20 ± 21.36 
82.14 ± 24.94 
50.28 ± 13.20 
4.12 ± 0.95 
102.01 ± 21.45 
2.21 ± 0.42 
 
124.08 ± 18.81 
61.95 ± 21.18 
42.65 ± 12.53 
4.14 ± 0.86 
83.16 ± 19.32  
2.45 ± 0.47 
109.38 ± 30.69 
56.96 ± 38.27 
43.15 ± 17.00 
3.63 ± 1.19 
75.78 ± 30.22 
2.41 ± 0.60 
95.61 ± 21.26 
37.06 ± 14.55 
34.57 ± 8.21 
3.88 ± 1.48 
58.46 ± 15.91 
2.55 ± 0.26 
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Table 3.5  Statistically significant differences when experimental groups were compared                        
       to control for CASMA parameters. GnRH peptides I and II indicated as I, II, 
       and concentrations of peptides in Molar. P-values of control versus peptides
       at significance level of p<0.05 used as a cut off point 
 
Variable Control 
versus (p<0.05) 
Time Increase (▲) 
Decrease (↓) 
VCL I 10-8   &   II 10-8 Immediate effect ↓ 
VSL I 10-8  &  II 10-8 Immediate effect ↓ 
VAP I 10-8  &  II 10-8 Immediate effect ↓ 
LIN I 10-8  &  II 10-8 Immediate effect ↓ 
MAD II 10-8 Immediate effect ▲ 
    
VCL I 10-8  &  II 10-8 15 minutes ↓ 
VSL I 10-8  &  II 10-8 15 minutes ↓ 
LIN I 10-8  &  II 10-8 15 minutes ↓ 
VAP I 10-8  &  II 10-8 15 minutes ▲ 
ALH I 10-8  &  II 10-8 15 minutes ▲ 
MAD II 10-8 15 minutes ▲ 
    
VCL I 10-8  &  II 10-8 30 minutes ↓ 
VSL II 10-8 30 minutes ↓ 
LIN I 10-8  &  II 10-8 30 minutes ↓ 
VAP II 10-8 30 minutes ↓ 
ALH I 10-8  &  II 10-8 30 minutes ↓ 
MAD I 10-8  &  II 10-8 30 minutes ▲ 
    
VCL I 10-8  &  II 10-8 60 minutes ↓ 
VSL I 10-8  &  II 10-8 60 minutes ↓ 
LIN I 10-8, II 10-8 & II 10-5 60 minutes ↓ 
VAP I 10-8  &  II 10-8 60 minutes ↓ 
ALH I 10-8  &  II 10-8 60 minutes ↓ 
MAD II 10-8 60 minutes ▲ 
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Figure 3.11
Curvilinear velocity (VCL) (+SD) for sperm treated with GnRH I & II at different concentrations for one hour
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Figure 3.12
Straight line velocity (VSL) (+SD) for sperm treated with GnRH I & II at different concentrations for one hour 
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Figure 3.13
Linearity (LIN) (+SD) for sperm treated with GnRH I & II at different concentrations for one hour
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Figure 3.14
Average path velocity (VAP) (+SD) for sperm treated with GnRH I & II at different concentrations for one hour
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Figure 3.15
Amplitude of lateral head displacement (ALH) (+SD) for sperm treated with GnRH I & II at different concentrations for one hour
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Figure 3.16
Mean angular displacement (MAD) (+SD) for sperm treated with GnRH I & II at various concentrations for one hour
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Figure 3.17
Percentage motility (+SD) for sperm treated with GnRH I & II at different concentrations for one hour 
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3.5.2     Sperm motility tracks 
Figures 3.18, 3.19 and 3.20 depict representative sperm motility tracks after SMQ analysis. 
The purpose of presenting these tracks is to show that in most cases it is possible to recognize 
patterns of sperm motility for different treatments. While these evaluations are subjective, it 
is useful in conjunction with the quantitative analysis in section 3.4.  
 
Figures 3.18A, B and C show sperm motility tracks of the control (A), GnRH I at 10-5M (B) 
and GnRH II 10-5M (C) at 60 minutes. For Figures A and B, the patterns appear quite similar. 
Both have fast swimming sperm (long tracks) as well as slow swimming sperm (short tracks) 
with a few immotile sperm (black dots) in Figure A. Shorter tracks are evident for Figure C 
and some immotile sperm for Figure A, but the patterns of movement seem to be similar. In 
this instance, the sperm motility pattern largely reflects the quantitative CASMA results as 
depicted in Table 3.4 and support the validity of the quantitative analysis (no statistical 
differences observed). 
 
Figure 3.19 A (control at 60 minutes), B (GnRH I at10-6M) and figure C (GnRH II 10-8M) 
look quite similar. Even though Figure C demonstrate more immotile sperm and shorter 
tracks, the CASMA results for these tracks showed no statistically significant differences for 
A, B and C (Table 3.4). However, on closer visual examination the tracks of Figure B are 
more irregular than those of Figure A. It visually emphasizes more “serrated” or irregular 
sperm motility tracks usually indicative of a higher ALH and lower LIN. These irregular 
tracks (Fig. 3.19B) show a resemblance to the early phases of hyper activation.  
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In contrast to the above observations, the sperm motility tracks in Figure 3.20 A (control at 
60 minutes), B (GnRH I at 10-8M) and Figure C (GnRH II at 10-8M) show distinctly different 
sperm motility patterns. These visual observations are in agreement with the CASMA 
analysis for this comparison (Table 3.4) which showed statistically significant differences for 
most parameters between control, GnRH I and GnRH II at 10-8M. Furthermore, these 
subjective sperm motility track analysis, support the observations that low concentrations of 
GnRH I and II seem to inhibit sperm motility while higher concentrations have no effect on 
sperm motility. 
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A Control 60 at minutes 
 
 
 
B       GnRH I 10-5M at 60 minutes 
 
 
 
 
C       GnRH II 10-5M at 60 minutes 
 
 
Figure 3.18   Representative sperm motility tracks for control, 
                      GnRH I and II at 10-5M for one hour after sperm                         
                    exposure. 
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A Control at 60 minutes 
 
 
 
 
 
B       GnRH I 10-6M at 60 minutes 
 
 
 
C       GnRH II 10-6M at 60 minutes 
 
 
Figure 3.19   Representative sperm motility tracks for control,  
                      GnRH I and II at 10-6M for one hour after sperm 
                      exposure. 
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A       Control at 60 minutes 
 
 
 
 
B       GnRH I 10-8M at 60 minutes 
 
 
 
C       GnRH II 10-8M at 60 minutes 
 
 
Figure 3.20   Representative sperm motility tracks for control, 
                      GnRH I and II at 10-8M for one hour after sperm  
                      exposure. 
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CHAPTER 4 
Discussion 
Although numerous reports have confirmed the well-established role of GnRH in 
spermatogenesis, the only data available on its direct effect in mature sperm are from the 
research done by Morales [Morales et al. 1999, Morales 1998 and Morales et al. 1994]. 
There appears to be no comparable published information on the in vitro effect of GnRH on 
non-human primate sperm, despite the significant use of this order as a model for human 
reproduction. Therefore, this is the first in vitro study to present data on the effect of GnRH 
in relation to sperm motility and acrosome status of the adult Vervet monkey. 
 
The wide tissue distribution and different functions of Gonadotropin-releasing hormone 
(GnRH) are well documented. There are numerous reports on the essential role of this 
peptide in the regulation of reproduction, viz. that it binds to a specific receptor located on 
the pituitary gland to cause the release of LH and FSH [Stojilkovic et al. 1994]. Furthermore, 
the reports of the inhibiting effect of GnRH antagonists and their possible use as a 
contraceptive agent, has paved the way for answering questions as to the specific role of 
GnRH in the male reproductive system. 
 
The local production of GnRH was reported in the testis and “GnRH-like” molecules were 
detected in human seminal plasma [Sokol et al. 1995]. The obvious investigations to follow 
were the effects of GnRH on mature sperm. In vitro studies have shown the expression of the 
GnRH receptor in rat and mouse testicular germ cells [Bull et al. 2000]. Even though a type 
II GnRH system is absent in humans, a receptor transcript in human sperm was found [Lee et 
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al. 2000, van Biljon et al. 2002]. Previous reports have described various other peptide 
receptors found on the acrosome region of the sperm and that these peptide molecules play a 
role in the acrosome reaction. The latter is a crucial event for the success of fertilization and 
takes place after the fertilizing spermatozoon binds to the surface of the zona pellucida (ZP). 
Thus, molecules that modify the ability of spermatozoa to bind to the ZP are physiologically 
important, as they could interfere with the fertilization process. 
 
Additional in vitro studies revealed that GnRH increased sperm binding to the human ZP by 
a direct effect on the sperm cells [Morales 1998] that is mediated by calcium influx into the 
sperm. Furthermore, it has been shown that GnRH antagonists inhibit sperm binding in a 
dose dependent manner [Morales et al. 1999] and that GnRH increased sperm-zona binding 
300% when Ca2+ and progesterone (P) were present in the culture medium,  progesterone as a 
stimulator of acrosome reaction [Morales et al. 2000, Morales et al. 2002]. However, neither 
GnRH nor any antagonists were reported to have any effect on the pattern of sperm 
movement and acrosome-reacted sperm.  
 
GnRH-like molecules have been reported in the ovary [Aten et al. 1987] and human 
follicular fluid [Ying et al. 1981]. It is postulated that spermatozoa might interact with GnRH 
(or with GnRH-like molecules) during their journey through the male and female genital 
tracts and this interaction might provide an increase or decrease in the zona-binding 
capabilities of the spermatozoa. The bulk of evidence indicates that fluids secreted in the 
upper female genital tract play a role in the fertilizing ability of sperm and follicular fluid has 
been reported to inhibit sperm binding [Munuce et al. 2004].       
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4. Electro ejaculation 
Rectal probe electro ejaculation is an accepted non-invasive procedure for the collection of 
non-human primate sperm [Gould et al. 1978]. The success of this method has been reported 
for the Rhesus monkey [Wickings and Nieschlag 1980], Vervet monkey [Seier et al. 1989], 
Cynomologus monkeys [Yeung et al. 1989] and the Baboon [Cseh et al. 2000]. The electric 
current used in electro ejaculation does not fragment sperm DNA, but a problem is the poor 
motility of the cells [Rall 1993] due to the difference in the membrane properties compared 
to sperm collected by other means [Cseh et al. 2000].   
 
Even though the technique of electro stimulation was satisfactory for this study, at times, 
some males produced low semen volumes and poor motility ejaculates. As some of the single 
males masturbate, it was difficult to ascertain their sexual abstinence at the time of sampling. 
Nonetheless, most of these samples were otherwise of good quality, with a high percentage 
of intact acrosomes, suggesting that their fertilization potential was not disrupted by the 
electro ejaculation process. Rectal probe electro ejaculation has been linked to retrograde 
ejaculations [Cseh et al. 2000], and this could explain the variation in ejaculates.  
 
4.1 Hams F10 extender 
There are many different culture media and treatments available for sperm recovery in 
clinical insemination programmes and for research purposes.  
 
In many species, including the Vervet monkey, sperm motility declines rapidly when 
spermatozoa are maintained in semen [Seier et al. 1989]. It is preferable to use a suitable 
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medium that will extend the motility of the sperm and to imitate the environment of the 
female reproductive tract. Hams F10 extender medium is widely used to improve the motility 
of ejaculated spermatozoa and is developed specifically to support the clonal growth of a 
variety of cells with specific nutritional requirements (Sigma, Cape Town).  
 
Therefore, Hams F10 was the culture medium used for the sperm swim-up technique in this 
study. The extender had to be freshly prepared for every experiment and pre-warmed at 37°C 
to prevent cold-shock to sperm. Hams F10 provided high-quality motile sperm throughout 
the experiment. This was consistent with other reports of motile sperm  recovery for in vitro 
fertilization [Vijayakumar et al. 1987] and the best sperm responses for the same medium 
[Oliva et al. 1991]. One disadvantage of Hams F10 reported in the literature is that it may 
increase reactive oxygen species (ROS) [Gomez and Aitken 1996] and mammalian 
spermatozoa were, in fact, the first cell type in which this activity was described [Macleod 
1943, Aitken and Fisher 1994].  Human spermatozoa are capable of generating O2- (super 
oxide) and H2O2 that is of fundamental biological importance in regulating the signal 
transduction pathways that control sperm capacitation [de Lamirande et al. 1997]. However, 
if the generation of these oxygen metabolites becomes elevated for any reason, this can result 
in oxidative stress that causes damage to the DNA and plasma membrane [Lopes et al. 1998, 
Baker and Aitken 2005]. Despite these concerns, it is unlikely that ROS generation via Hams 
F10 affected the results over one hour. The results of the control samples were consistent 
with a previous report of high percentage motility (>88%) and kinematic parameters, 
representing high quality sperm, when Hams F10 was used as culture medium [van der Horst 
et al. 1999]. 
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4.2      Swim-up incubation 
Under physiological conditions, ejaculated spermatozoa must be washed free from seminal 
plasma in order to undergo capacitation, which is necessary before they undergo the 
acrosome reaction [Wang et al. 1993]. Prolonged exposure to seminal plasma results in a 
marked decline in both motility and viability and spermatozoa are damaged by reactive 
oxygen species emanating from seminal leukocytes and damaged spermatozoa [Aitken and 
Clarkson 1988]. It is therefore important that spermatozoa must be separated from the 
seminal environment as soon as possible. The swim-up procedure accomplishes this 
separation, and enables the selection of populations of highly motile spermatozoa. 
 
In this study, there were two factors that needed consideration concerning the sperm samples. 
The first factor was the rapid decline in motility of Vervet monkey sperm in seminal plasma 
[Seier et al. 1989] and secondly, the poor motility of sperm reported after electro ejaculation 
[Rall 1993]. Since the sperm membrane of spermatozoa can be damaged by centrifugation, 
cell debris and leukocytes, the direct swim-up method from semen was used [WHO 1999].  
 
Most of the semen samples coagulated soon after ejaculation. The samples could not be left 
at room temperature to liquefy, as in the case of humans, because of the deterioration of 
semen quality after 30 minutes as reported by Seier et al. [1989].  No enzymatic liquefactions 
were used. Immediately after estimation of the motility and forward progression evaluations, 
Hams F10 was layered on top of the coagulum where motile spermatozoa then swam into the 
culture medium. 
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Both swim-up methods resulted in a highly motile sperm population that was required for the 
completion of each experiment. The success  of the swim-up technique in this study showed 
agreement with previous findings that suggested this method offers the possibility of 
selecting spermatozoa with better motility, acrosomal integrity and the ability to undergo the 
acrosome reaction (AR) [Esteves et al. 2000]. 
 
4.3 Acrosomal integrity 
Only spermatozoa with normal intact acrosomes undergo physiological acrosome reaction, 
which is essential for the spermatozoa to penetrate the zona pellucida and to fuse with the 
oolemma [Morales and Llanos 1996]. A normal sperm sample should contain a high 
proportion of spermatozoa with intact acrosomes [Tesarik 1989, Cummins et al. 1991, 
Henkel et al. 1993] and the data from this study demonstrated that fluorescence pattern I 
(intact acrosome) was the dominant characteristic for the control, (vehicle) propylene glycol 
0.2% and GnRH treated groups (GnRH at 10-5M, GnRH at 10-6M and GnRH at 10-8M).  A 
striking feature of acrosome staining and scoring for the different fluorescent patterns is the 
large variability encountered from sample to sample leading to the large standard deviations. 
At times a trend seemed to appear in acrosome staining, but in this investigation the treated 
sperm samples was never statistically significantly different from the control or vehicle.    
 
In Table 4.1, the data for acrosome loss in the controls of this study are compared to other 
reports for Vervet monkey sperm. 
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Table 4.1  Comparison of acrosome status reported for Vervet monkey sperm 
Acrosome staining 
 
Mean 
% 
SD 
 
n 
 
Source 
 
Intact acrosome 
 
61.2 
55.56 
97.11 
3.15 
2.30 
4.80 
10 
5 
6 
Conradie et al. 1994 
Seier et al. 2003 
De Villiers, 2006 (this thesis) 
 
Equatorial staining 16.80 
13.70 
1.31 
3.42 
5.16 
3.37 
10 
5 
6 
Conradie et al. 1994 
Seier et al. 2003 
De Villiers, 2006 (this thesis) 
 
Absent acrosome 
 
4.60 
16.36 
1.58 
2.12 
5.70 
3.22 
10 
5 
6 
Conradie et al. 1994 
Seier et al. 2003 
De Villiers, 2006 (this thesis) 
 
 
In this study, the percentage of intact acrosomes in the controls was much higher compared 
to previous reports for Vervet monkey sperm, while also demonstrating much lower figures 
for acrosome loss and absent acrosomes. The same trend was found in the GnRH treated 
groups. Two factors need to be considered when comparing these results. Firstly, a different 
staining method was used in this study and, secondly, the “patchy acrosome” variable was 
very difficult to distinguish from the bright pattern (intact acrosome). The uncertainty in 
distinguishing between intact acrosome and patchy acrosomes necessitated the investigator of 
this study to group patterns I and II together. This explains the discrepancy in the results as 
indicated in Table 4.1.  
 
In conclusion, regardless of the difficulty in identifying the acrosome pattern II (patchy), the 
high numbers of intact acrosomes found in the treated groups suggest that the different 
concentrations of GnRH I & II had little or no effect on sperm plasma membrane 
composition and potentially on the functional changes in acrosome status. These results are 
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in agreement with Morales [1998] who indicated that GnRH had no effect on the acrosome 
reaction. The same author also reported that large concentrations of GnRH and Ca2+ 
antagonists showed different results regarding the acrosome reaction but progesterone 
treatment enhanced the acrosome effect. GnRH antagonists were not evaluated in this study.  
 
 4.4 Sperm motility 
Sperm motility is a prerequisite for achieving fertilization. The male gametes must travel 
through cervical mucus and the female reproductive tract in order to penetrate the egg 
[Cooper 1986]. Thus, movement of sperm is a widely accepted parameter for assessment in 
male fertility. 
 
4.4.1 Total percentage sperm motility 
The percentage sperm motility in the controls of this study was comparable to previous 
reports for the Vervet monkey [Seier et al. 1989, Sankai et al. 1997 and van der Horst et al. 
1999] and was not affected by high concentrations of GnRH I and II (10-5M to 10-6M). 
However, both GnRH I and II inhibited sperm motility (percentage) over an hour period at 
10-8M compared to the control values. It was particularly GnRH II, which depressed the 
percentage motile sperm from 90 ± 11.3 SD in the control to 49 ± 23.4 after one hour  
(10-8M). This effect should, furthermore, be considered as biphasic in the context of a 
physiological response [Fourie 1998] given that Tripolin, a GnRH agonist, was shown to 
exert a double inhibitory-stimulatory action on cell growth when tested on two prostatic cell 
lines, depending on the dose and environmental conditions [Ravenna et al. 2000]. 
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It is therefore evident that GnRH I and GnRH II in vitro inhibit the motility of Vervet 
monkey sperm at low/physiological levels (10-8M). However, it has been previously reported 
that neither GnRH nor the antagonists at different concentrations affected the motility of 
human sperm in vitro [Morales et al. 1994]. Considering the fact that a functional type II 
GnRH receptor is present in primates but not in humans, the results of this study may 
accordingly reflect differences between species or provide the need for a new approach. The 
potential physiological significance of GnRH/sperm interaction and the percentage motility 
results will be discussed in conjunction with the CASMA results. 
 
4.4.2  Computer Aided Sperm Motility Analysis (CASMA)  
Only low concentrations of GnRH I and II (10-8M) affected the kinematic parameters of 
sperm. These effects were evident from initial exposure to 60 minutes. There was a decline in 
most parameters (VCL, VSL, VAP, LIN, and ALH) but an increase in MAD over time after 
GnRH I and II exposure. The CASMA results therefore followed the same trend as the 
percentage motility results in this investigation.  
 
A decrease in VCL, VSL and VAP reflects a decrease in the vigour of motility of a sperm 
population (Katz 1991, van der Horst 1995, van der Horst et al. 1999). Both GnRH I and II, 
particularly at low concentrations (10-8M) decreased the vigour of sperm movement.  
 
Alteration in LIN, ALH and MAD signifies that the pattern of sperm motion changed. A 
decrease in LIN and an increase in MAD show a decrease in sperm progression. In this 
investigation, LIN and ALH decreased but MAD increased after exposure to GnRH I and II 
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at low concentrations (10-8M). When LIN decreases and MAD increases, sperm swim less 
progressively forward. When ALH decreases, there is a lower oscillation of the sperm head 
in relation to the VAP track.  
 
It is evident from the above that sperm vigour, as well as forward sperm progression, was 
compromised when Vervet monkey sperm were exposed to low concentrations of GnRH I or 
II. The results of this investigation clearly show that most CASMA parameters are inhibited 
by GnRH I and II and these quantitative sperm motility parameters were significantly 
decreased. This will be discussed further under 4.5.4. 
 
4.4.3  Sperm track analysis 
The sperm track analysis represented the actual sperm swimming trajectories. Visual 
differences in representative sperm tracks cannot replace formal statistical models but are  
similar to ICONS and assist in visualizing differences in sperm swimming patterns and 
sperm morphology [e.g. Fourier blobs, Chernoff faces [Cleveland and McGill 1985], star 
symbol plot analysis [van der Horst et al. 1991, van der Horst 1995, van der Horst et al. 
1999)]. ICONS are indispensable exploratory tools and once statistical differences have been 
established as in this investigation, greatly assist in visualizing/supporting differences in 
sperm tracks. 
 
In this study, comparisons of sperm tracks representing different treatments supported the 
findings as verified statistically. In additition, “new patterns” of sperm motility emerged 
when sperm were exposed for one hour to GnRH I at 10-6M as indicated in the Results 
 
 
 
 
 103
section (Fig.3.19B, p91). In this instance, the sperm motility pattern resembled the early 
stages of hyper activation. It may be possible that longer exposure of sperm to GnRH I at  
10-6M (>one hour) helps to trigger the hyper activated state. Unfortunately, sperm incubation 
in this study was restricted to one hour. It is thus hypothesized that GnRH I and II inhibit 
sperm motility at low concentrations (10-8M) but may be stimulatory at higher concentrations 
after longer incubation. This hypothesis should be tested in future studies. 
      
4.4.4 Hypothesis on GnRH I and II in relation to sperm motility       
development/inhibition and conclusion 
 
Figure 4.1 (A to D) shows various GnRH receptor sites in the male and female reproductive 
systems. Virtually every compartment to which sperm and oocytes are exposed seems to be 
associated with some form of either GnRH and/or a GnRH receptor.  
 
The importance of GnRH in spermatogenesis is well documented. A low affinity receptor for 
GnRH I, in some reproductive tissue, has been reported, as well as the presence of high-
affinity specific binding sites and activity for GnRH II. One of these sites of action is the 
fertilizing sperm. A GnRH II receptor mRNA is expressed in the human sperm, although the 
functional protein is yet to be defined [van Biljon et al. 2002]. 
 
Investigators concluded that the composition of the extra cellular matrix of the female genital 
tract is the most favourable environment for sperm function/survival. They further stated that 
the sperm are able to respond to environmental cues within this milieu, and fertilization may 
not be limited to a random interaction between sperm and oocyte [Durkee et al. 1998]. Thus 
the female tract, and possibly the oocyte, “communicates” with the sperm by the elaboration 
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of the hypothesized factors.  The GnRH found in the female genital tract could play a very 
important role in this unique mechanism. At some stage during transport, sperm might 
interact with GnRH at several possible sites along the male and female genital tract (see 
Figure 4.1). For example, GnRH produced by Sertoli cells could influence sperm during 
spermatogenesis, or during ejaculation the sperm cells may interact with GnRH present in 
seminal plasma.  
 
During their transit throughout the oviduct, the sperm may cooperate with GnRH transferred 
by the products of ovulation. Reports indicate that fluids secreted by the upper female genital 
tract can have a role in synchronizing the acquisition of sperm fertilizing ability [Barratt and 
Cooke 1991] and that human follicular fluid (hFF) can result in a lower fertilizing ability by 
modulating sperm function [Munuce et al. 2004]. Based on these facts, and the presence of 
GnRH in hFF [Ying et al. 1981, Li et al. 1993], it is suggested that GnRH in the female 
reproductive tract could play a role in the selection phase of sperm prior to fertilization in 
vivo. The results of this study support this view, since they clearly demonstrated a sperm 
motility-inhibiting effect of a low-dose exposure of GnRH I & II on Vervet sperm in vitro.   
 
It may furthermore be possible that GnRH I and II play a modulatory role in sperm motility 
during different phases of sperm maturation, as well as during their transit particularly in the 
female reproductive system. Before a sperm fertilizes the oocyte, it needs to undergo 
capacitation; otherwise the acrosome reaction cannot take place. One important landmark of 
capacitation is hyperactivation that is typically associated with a vast increase in VCL and 
ALH (200-300%) and a decline in LIN to less than 50% [Mortimer 1994]. It may be possible 
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that higher concentrations of GnRH I and/or II may facilitate hyper activation over a longer 
exposure time than one hour. 
 
However, the specific role of GnRH, and more importantly its mechanism of action within 
the sperm, remains to be clearly defined. There is currently no evidence for GnRH receptors 
on Vervet monkey sperm. Future studies should concentrate on the effect of a GnRH 
antagonist on sperm motility along with the potential presence of GnRH receptors on the 
sperm. 
 
The Vervet monkey has proved to be a valuable model in reproductive physiology research.  
Should the presence of a GnRH receptor be confirmed in monkey sperm, this would provide 
an opportunity to investigate and address the many concerns regarding GnRH and sperm 
interaction. 
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* Testis, Sertoli cells, Spermatogenic cells and Leydig 
cells (rat & human) [Kadar et al. 1988, Bahk et al.  
1995] 
* Testicular germ cells (rat & mouse) [Bull et al. 2000] 
* Prostate and seminal plasma (rat & human) [Azad et 
al. 1993, Sokol et al. 1985] 
* Ejaculated sperm (human) [Morales 1998, van Biljon 
et al. 2002] 
 
* Follicular fluid (human) [Ying et al. 1981] 
* Ovary (baboon) and placenta (human) [Khodr and Siler-
Khodr 1980, Aten et al. 1987, Siler-Khodr et al. 2003] 
* Corpus luteum (human) [Bramley et al. 1985] 
* Fallopian tube and endometrium (human) [Raga et al. 
1998, Casan et al. 2000] 
* Fertilization (human) [Morales 1998, Casan et al. 2000] 
Figure 4.1 GnRH sites (*) in the male and female reproductive systems.  
  Sperm traveling through male and female genital ducts could be exposed to  
  GnRH [Photomicrographs A, B & D: Ganong 1999, Diagram C: Hafez 1987] 
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